<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26967321</article-id><article-id pub-id-type="pmc">4788153</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0150955</article-id><article-id pub-id-type="publisher-id">PONE-D-15-50475</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug Metabolism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Metabolites</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Salts</subject><subj-group><subject>Sulfates</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme Chemistry</subject><subj-group><subject>Enzyme Metabolism</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Behavioral Pharmacology</subject><subj-group><subject>Recreational Drug Use</subject><subj-group><subject>Mdma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Isomers</subject><subj-group><subject>Stereoisomers</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Stereochemistry</subject><subj-group><subject>Isomerism</subject><subj-group><subject>Isomers</subject><subj-group><subject>Stereoisomers</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans</article-title><alt-title alt-title-type="running-head">CYP2D6-Dependent Chiral Pharmacokinetics of MDMA and Metabolites</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Steuer</surname><given-names>Andrea E.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Schmidhauser</surname><given-names>Corina</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tingelhoff</surname><given-names>Eva H.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schmid</surname><given-names>Yasmin</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rickli</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kraemer</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liechti</surname><given-names>Matthias E.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Forensic Pharmacology &#x00026; Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Hashimoto</surname><given-names>Kenji</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Chiba University Center for Forensic Mental Health, JAPAN</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: AES TK MEL. Performed the experiments: AES CS EHT YS AR. Analyzed the data: AES CS EHT. Contributed reagents/materials/analysis tools: TK MEL. Wrote the paper: AES TK MEL.</p></fn><corresp id="cor001">* E-mail: <email>andrea.steuer@irm.uzh.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>3</issue><elocation-id>e0150955</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Steuer et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Steuer et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0150955.pdf"/><abstract><p>3,4-methylenedioxymethamphetamine (MDMA; ecstasy) metabolism is known to be stereoselective, with preference for <italic>S</italic>-stereoisomers. Its major metabolic step involves CYP2D6-catalyzed demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by methylation and conjugation. Alterations in CYP2D6 genotype and/or phenotype have been associated with higher toxicity. Therefore, the impact of CYP2D6 function on the plasma pharmacokinetics of MDMA and its phase I and II metabolites was tested by comparing extensive metabolizers (EMs), intermediate metabolizers (IMs), and EMs that were pretreated with bupropion as a metabolic inhibitor in a controlled MDMA administration study. Blood plasma samples were collected from 16 healthy participants (13 EMs and three IMs) up to 24 h after MDMA administration in a double-blind, placebo-controlled, four-period, cross-over design, with subjects receiving 1 week placebo or bupropion pretreatment followed by a single placebo or MDMA (125 mg) dose. Bupropion pretreatment increased the maximum plasma concentration (C<sub>max</sub>) and area under the plasma concentration-time curve from 0 to 24 h (AUC<sub>24</sub>) of <italic>R-</italic>MDMA (9% and 25%, respectively) and <italic>S-</italic>MDMA (16% and 38%, respectively). Bupropion reduced the C<sub>max</sub> and AUC<sub>24</sub> of the CYP2D6-dependently formed metabolite stereoisomers of DHMA 3-sulfate, DHMA 4-sulfate, and 4-hydroxy-3-methoxymethamphetamine (HMMA sulfate and HMMA glucuronide) by approximately 40%. The changes that were observed in IMs were generally comparable to bupropion-pretreated EMs. Although changes in stereoselectivity based on CYP2D6 activity were observed, these likely have low clinical relevance. Bupropion and hydroxybupropion stereoisomer pharmacokinetics were unaltered by MDMA co-administration. The present data might aid further interpretations of toxicity based on CYP2D6-dependent MDMA metabolism.</p></abstract><funding-group><funding-statement>This work was supported by the Swiss National Science Foundation SNF (<ext-link ext-link-type="uri" xlink:href="http://www.snf.ch">www.snf.ch</ext-link>), Grant Number 320030_149493, to MEL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="2"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is an illicit amphetamine derivative that is used recreationally, usually as a 1:1 mixture of its <italic>R</italic>- and <italic>S</italic>-enantiomers. MDMA enhances feelings of energy, friendliness, euphoria, and empathy [<xref rid="pone.0150955.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0150955.ref002" ref-type="bibr">2</xref>]. In animals, the <italic>S</italic>-enantiomer of MDMA or its active metabolite 3,4-methylenedioxyamphetamine (MDA) are more potent than the <italic>R</italic>-enantiomers [<xref rid="pone.0150955.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0150955.ref006" ref-type="bibr">6</xref>]. Addionally, <italic>S</italic>-MDMA has more amphetamine distinctive effects [<xref rid="pone.0150955.ref007" ref-type="bibr">7</xref>] whereas <italic>R</italic>-MDMA and <italic>R</italic>-MDA have more hallucinogen-like effects than the <italic>S</italic>-enantiomers [<xref rid="pone.0150955.ref008" ref-type="bibr">8</xref>] Acute toxicity (e.g., tachycardia, hypertension, hyperthermia, and hepatotoxicity) and even fatalities have been associated with the short-term use of MDMA [<xref rid="pone.0150955.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0150955.ref010" ref-type="bibr">10</xref>]. Neurotoxic effects on serotonergic neurons, presumably via the bioactivation and formation of glutathione adducts [<xref rid="pone.0150955.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0150955.ref018" ref-type="bibr">18</xref>], are still being investigated and controversially discussed in terms of species-dependence and dosing [<xref rid="pone.0150955.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0150955.ref021" ref-type="bibr">21</xref>]. Importantly, alterations of cytochrome P450 (CYP)-mediated MDMA metabolism were shown to influence neurotoxicity [<xref rid="pone.0150955.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0150955.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0150955.ref022" ref-type="bibr">22</xref>].</p><p>As shown in <xref ref-type="fig" rid="pone.0150955.g001">Fig 1</xref>, in humans, MDMA is mainly metabolized by CYP2D6-mediated <italic>O</italic>-demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by catechol-<italic>O</italic>-methyltransferase (COMT) <italic>O</italic>-methylation mainly to 4-hydroxy-3-methoxymethamphetamine (HMMA). DHMA is further sulfated mainly by sulfotransferases (SULTs) to DHMA 3-sulfate and DHMA 4-sulfate. HMMA can be further conjugated by UDP-glucuronyltransferases (UGTs) or SULTs. DHMA 3-sulfate, HMMA sulfate, and HMMA glucuronide were shown to be the main metabolites in plasma [<xref rid="pone.0150955.ref023" ref-type="bibr">23</xref>] and urine [<xref rid="pone.0150955.ref024" ref-type="bibr">24</xref>], whereas free DHMA and HMMA were not detectable or only in negligible amounts. A minor pathway includes demethylation to MDA, mainly by CYP2B6, CYP1A2, and CYP3A4 [<xref rid="pone.0150955.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0150955.ref026" ref-type="bibr">26</xref>], followed by demethylenation, <italic>O</italic>-methylation, and conjugation [<xref rid="pone.0150955.ref027" ref-type="bibr">27</xref>&#x02013;<xref rid="pone.0150955.ref029" ref-type="bibr">29</xref>]. Differences in the metabolism and plasma pharmacokinetics of the two enantiomers of MDMA were reported <italic>in vitro</italic> [<xref rid="pone.0150955.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0150955.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0150955.ref032" ref-type="bibr">32</xref>] and <italic>in vivo</italic> [<xref rid="pone.0150955.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0150955.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0150955.ref033" ref-type="bibr">33</xref>&#x02013;<xref rid="pone.0150955.ref036" ref-type="bibr">36</xref>], with higher <italic>R</italic>-MDMA blood concentrations and preferred elimination (metabolism and excretion) of <italic>S</italic>-stereoisomers.</p><fig id="pone.0150955.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g001</object-id><label>Fig 1</label><caption><title>Main metabolic steps of MDMA.</title><p>MDMA is mainly metabolized by CYP2D6-mediated <italic>O</italic>-demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by catechol-<italic>O</italic>-methyltransferase (COMT) <italic>O</italic>-methylation mainly to 4-hydroxy-3-methoxymethamphetamine (HMMA). DHMA is further sulfated mainly by sulfotransferases (SULTs) to DHMA 3-sulfate (DHMA 3S) and DHMA 4-sulfate (DHMA 4S). HMMA can be further conjugated by UDP-glucuronyltransferases to HMMA glucuronide (HMMA G) or sulfotransferases to HMMA sulfate (HMMA S). Bold arrows indicate preferences in depicted metabolic reaction for <italic>R</italic>- or <italic>S</italic>-stereoisomer, respectively. Only sulfation of HMMA revealed no enantiomeric preferences.</p></caption><graphic xlink:href="pone.0150955.g001"/></fig><p>Although CYP2D6 only accounts for approximately 2% of hepatic CYP enzymes, it is responsible for approximately 19% of drug metabolism [<xref rid="pone.0150955.ref037" ref-type="bibr">37</xref>, <xref rid="pone.0150955.ref038" ref-type="bibr">38</xref>]. Among the CYP enzymes, CYP2D6 is the most susceptible to genetic polymorphisms, with more than 100 allelic variants [<xref rid="pone.0150955.ref037" ref-type="bibr">37</xref>, <xref rid="pone.0150955.ref038" ref-type="bibr">38</xref>], which can be phenotypically classified into four main groups: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM), and ultra-rapid metabolizer (UM). Extensive metabolizers have fully functional enzymes, whereas IMs and PMs exhibit reduced activity and UMs exhibit increased enzyme activity. Among Caucasians, EMs, IMs, PMs, and UMs represent approximately 70&#x02013;80%, 10&#x02013;17%, 5&#x02013;10%, and 3&#x02013;5% of the population, respectively. The participation of CYP2D6 in the metabolism of MDMA may suggest that individuals with extensive or even ultrafast metabolism might be at a higher risk for neurotoxic effects, whereas IMs and/or PMs are more prone to acute MDMA toxicity [<xref rid="pone.0150955.ref017" ref-type="bibr">17</xref>]. However, finding sufficient numbers of UMs and/or PMs for controlled MDMA administration studies is rather difficult. Co-administering known CYP2D6 inhibitors (e.g., the selective serotonin reuptake inhibitor [SSRI] paroxetine or fluoxetine) might mimic the IM or PM genotype. Segura et al. successfully used this approach with paroxetine as a CYP2D6 inhibitor in seven EMs who were orally administered MDMA [<xref rid="pone.0150955.ref039" ref-type="bibr">39</xref>]. However, the analysis was only performed with racemic MDMA and free metabolites after conjugate cleavage and did not take into account potential differences in stereoisomers and the abundance of all metabolites. Bupropion acts as a selective norepinephrine/dopamine reuptake inhibitor. It was recently used in an interaction study with MDMA to explore the role of dopamine in the psychotropic effects of MDMA [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>]. Bupropion is commonly used for the treatment of depression and smoking cessation and has been studied for a number of other diseases (e.g., bipolar disorder and attention-deficit/hyperactivity disorder) and weight loss [<xref rid="pone.0150955.ref041" ref-type="bibr">41</xref>, <xref rid="pone.0150955.ref042" ref-type="bibr">42</xref>]. It is extensively metabolized mainly to hydroxybupropion, primarily by CYP2B6 as shown in <xref ref-type="fig" rid="pone.0150955.g002">Fig 2</xref>, and to a lesser extent to dehydrobupropion (erythrohydro- and threohydrobupropion). Plasma pharmacokinetics were shown to differ between stereoisomers with higher concentrations of <italic>R</italic>-bupropion and <italic>R</italic>,<italic>R</italic>-hydroxybupropion [<xref rid="pone.0150955.ref043" ref-type="bibr">43</xref>], whereas higher pharmacological potency of <italic>S</italic>,<italic>S</italic>-hydroxybupropion was found compared with both <italic>R</italic>,<italic>R</italic>-hydroxybupropion and racemic bupropion. The effects were comparable between racemic bupropion and each of its enantiomers <italic>in vitro</italic>, most likely because of its rapid racemization under physiological conditions. Bupropion and particularly erythrohydro- and threohydrobupropion have previously been shown to inhibit CYP2D6 [<xref rid="pone.0150955.ref041" ref-type="bibr">41</xref>, <xref rid="pone.0150955.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0150955.ref045" ref-type="bibr">45</xref>].</p><fig id="pone.0150955.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g002</object-id><label>Fig 2</label><caption><title>Main metabolic step of bupropion.</title><p>Chemical structures of bupropion enantiomers and their main metabolites R,R- and S,S-hydroxybupropion formed through CYP2B6-mediated hydroxylation.</p></caption><graphic xlink:href="pone.0150955.g002"/></fig><p>The aim of the present study was to assess the contribution of CYP2D6 to the chiral pharmacokinetics of MDMA and its phase I and II metabolites in samples that were collected during a previous pharmacodynamic interaction study [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>]. Thirteen EMs and three IMs participated in the study, allowing us to explore the effects of genetic differences in CYP2D6 function on MDMA metabolism. Bupropion was also repeatedly administered prior to MDMA administration to inhibit CYP2D6 activity, thus allowing exploration of the effect of pharmacologically inhibiting CYP2D6 on MDMA metabolism in all of the study participants.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Chemicals and reagents</title><p>The sources of the chemicals and reagents that were used for the MDMA analysis are provided in detail in a previous study [<xref rid="pone.0150955.ref046" ref-type="bibr">46</xref>]. Methanolic solutions of hydrochlorides of racemic bupropion (1 mg/ml) and bupropion-d9 (0.1 mg/ml) and acetonitrilic solutions of hydroxybupropion (1 mg/ml) and hydroxybupropion-d6 (0.1 mg/ml) were obtained from Cerilliant and delivered via Sigma-Aldrich (Buchs, Switzerland).</p></sec><sec id="sec004"><title>Clinical study</title><p>The study used a double-blind, placebo-controlled, crossover design with four experimental test sessions (placebo+placebo, bupropion+placebo, placebo+MDMA, and bupropion+MDMA) in 16 healthy Caucasian subjects (eight men and eight women) with a mean &#x000b1; SD age of 24.3 &#x000b1; 2.2 years and a body mass index of 22.7 &#x000b1; 2.1 kg/m<sup>2</sup> as described in detail in a previous study [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>]. Washout periods between test sessions were at least 10 days. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Canton of Basel, Switzerland, and the Swiss Agency for Therapeutic Products (Swissmedic). The study was registered at ClinicalTrials.gov (NCT01771874). All of the subjects provided written informed consent and were paid for their participation. Bupropion (Wellbutrin XR 150 mg, GlaxoSmithKline, Munchenbuchsee, Switzerland) or placebo was administered once daily at a dose of 150 mg for 3 days, followed by administration of 300 mg once daily for 4 days before the test days. On the test day, the last dose of bupropion or placebo (300 mg) was administered at 8:00 AM, 2 h before MDMA administration (125 mg MDMA hydrochloride, Lipomed, Arlesheim, Switzerland), or placebo was administered at 10:00 AM. Blood samples were collected -2, 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 h after MDMA or placebo administration. All of the subjects were genotyped [<xref rid="pone.0150955.ref047" ref-type="bibr">47</xref>] and phenotyped [<xref rid="pone.0150955.ref048" ref-type="bibr">48</xref>] for CYP2D6 activity. The study included 13 EMs, three IMs, and no PMs (genotyping and phenotyping congruent) [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>]. Subjects were also genotyped for CYP2B6 (reduced-activity single nucleotid polymorphism rs3745274 (516G&#x0003e;T, CYP2B6*6 or CYP2B6*9) using commercial TaqMan assay (LuBio Science, Lucerne, Switzerland). There were 9 subjects with the G/G, 6 subjects with the G/T and one subject with the T/T genotype. Subjects with G/T or T/T genotype were considered to have a reduced CYP2B6 function.</p></sec><sec id="sec005"><title>Chiral analysis of MDMA and metabolites</title><p>Blood plasma samples were analyzed non-stereoselectively as reported previously [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>] and reanalyzed for the present report using liquid chromatography-mass spectrometry/mass spectrometry after chiral derivatization with Marfey&#x02019;s reagent as described previously [<xref rid="pone.0150955.ref046" ref-type="bibr">46</xref>]. The method was fully validated, including selectivity, recovery, matrix effects, bias and imprecision, stability, and limit of quantification [<xref rid="pone.0150955.ref046" ref-type="bibr">46</xref>].</p></sec><sec id="sec006"><title>Chiral analysis of bupropion and hydroxybupropion</title><p>Blood plasma samples were analyzed stereoselectively for <italic>R-</italic> and <italic>S-</italic>bupropion and their major metabolites <italic>R</italic>,<italic>R-</italic> and <italic>S</italic>,<italic>S-</italic>hydroxybupropion according to a previous study [<xref rid="pone.0150955.ref043" ref-type="bibr">43</xref>] with slight modifications as described in the supporting information (<xref ref-type="supplementary-material" rid="pone.0150955.s004">S1 text</xref>). The method was fully validated according to national and international guidelines [<xref rid="pone.0150955.ref049" ref-type="bibr">49</xref>, <xref rid="pone.0150955.ref050" ref-type="bibr">50</xref>].</p></sec><sec id="sec007"><title>Pharmacokinetic analysis</title><p>Maximum plasma concentration (C<sub>max</sub>), time to reach C<sub>max</sub> (t<sub>max</sub>), area under the plasma concentration-time curve from 0 to 24 h (AUC<sub>24</sub>), AUC from time 0 to infinity (AUC<sub>&#x0221e;</sub>), and elimination half-life (t<sub>1/2</sub>) were calculated for all analytes and apparent total clearance (Cl/F) for <italic>R</italic>- and <italic>S</italic>-MDMA using noncompartmental methods (PK solutions 2.0 software, Summit Research Services, Montrose, CO, USA). The time interval after dosing until detection of the first positive sample was designated as the time of first detection (t<sub>onset</sub>). Wilcoxon matched-pairs tests (95% confidence interval) were used to test for within-subjects differences in pharmacokinetic parameters between the <italic>R</italic> and <italic>S</italic> stereoisomers and between different treatment conditions (placebo-MDMA <italic>vs</italic>. bupropion-MDMA, bupropion-placebo <italic>vs</italic>. bupropion-MDMA). Mann-Whitney tests (95% confidence interval) were used to test for between-subject differences between CYP2D6 EMs (<italic>n</italic> = 13) and CYP2D6 IMs (<italic>n</italic> = 3). The statistical analyses were performed using Prism 6.00 software (GraphPad Software, La Jolla, CA, USA).</p></sec></sec><sec sec-type="results" id="sec008"><title>Results</title><sec id="sec009"><title>Chiral pharmacokinetics of MDMA and metabolites</title><p>Plasma concentration-time profiles for MDMA and metabolites in placebo+MDMA-treated CYP2D6 EMs and CYP2D6 IMs and bupropion+MDMA-treated EMs are presented in <xref ref-type="fig" rid="pone.0150955.g003">Fig 3</xref>. The pharmacokinetic parameters for all three groups are listed in <xref ref-type="table" rid="pone.0150955.t001">Table 1</xref>. MDMA concentrations were significantly higher in bupropion+MDMA CYP2D6 EMs compared with placebo+MDMA-treated CYP2D6 EMs (9% and 16% increases in C<sub>max</sub> and 25% and 38% increases in AUC<sub>24</sub> for <italic>R</italic>- and <italic>S</italic>-enantiomers, respectively). MDMA concentrations marginally increased in CYP2D6 IMs compared with the other groups, but the difference was not significant because of the small number of subjects in the IM group. Bupropion pretreatment reduced the elimination of MDMA, with a significant prolongation of t<sub>1/2</sub> for <italic>R</italic>-MDMA (31%) and <italic>S</italic>-MDMA (26%) and a reduction of Cl/F (-23% and -31%, respectively). The elimination of MDMA was also marginally reduced in CYP2D6 IMs compared with EMs, but the reduction was not significant.</p><table-wrap id="pone.0150955.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.t001</object-id><label>Table 1</label><caption><title>Pharmacokinetic data of MDMA.</title></caption><alternatives><graphic id="pone.0150955.t001g" xlink:href="pone.0150955.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Cmax [&#x003bc;mol/l]</th><th align="center" colspan="2" rowspan="1">tmax [h]</th><th align="center" colspan="3" rowspan="1">AUC0-24h [&#x003bc;mol/l*h-1]</th><th align="center" colspan="2" rowspan="1">AUCtotal [&#x003bc;mol/l*h-1]</th><th align="center" colspan="2" rowspan="1">t<sub>1/2</sub> [h]</th><th align="center" colspan="2" rowspan="1">CL/F [l/h]</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R/S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R/S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MDMA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM</td><td align="center" rowspan="1" colspan="1">0.69 (0.17)</td><td align="center" rowspan="1" colspan="1">0.56 (0.15)</td><td align="center" rowspan="1" colspan="1">1.2 (0.1)</td><td align="center" rowspan="1" colspan="1">2.9 (0.8)</td><td align="center" rowspan="1" colspan="1">2.1 (0.7)</td><td align="center" rowspan="1" colspan="1">8.7 (2.3)</td><td align="center" rowspan="1" colspan="1">4.9 (1.4)</td><td align="center" rowspan="1" colspan="1">1.8 (0.2)</td><td align="center" rowspan="1" colspan="1">10.4 (3.6)</td><td align="center" rowspan="1" colspan="1">5.1 (1.5)</td><td align="center" rowspan="1" colspan="1">8.2 (2.4)</td><td align="center" rowspan="1" colspan="1">4.5 (0.6)</td><td align="center" rowspan="1" colspan="1">40.4 (14.2)</td><td align="center" rowspan="1" colspan="1">72.8 (26.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IM</td><td align="center" rowspan="1" colspan="1">0.85 (0.30)</td><td align="center" rowspan="1" colspan="1">0.72 (0.23)</td><td align="center" rowspan="1" colspan="1">1.2 (0.1)</td><td align="center" rowspan="1" colspan="1">2.8 (0.9)</td><td align="center" rowspan="1" colspan="1">2.3 (0.6)</td><td align="center" rowspan="1" colspan="1">11.4 (3.3)</td><td align="center" rowspan="1" colspan="1">6.8 (2.0)</td><td align="center" rowspan="1" colspan="1">1.7 (0.1)</td><td align="center" rowspan="1" colspan="1">14.5 (4.3)</td><td align="center" rowspan="1" colspan="1">7.1 (2.0)</td><td align="center" rowspan="1" colspan="1">10.3 (3.6)</td><td align="center" rowspan="1" colspan="1">5.1 (0.9)</td><td align="center" rowspan="1" colspan="1">29.8 (7.4)</td><td align="center" rowspan="1" colspan="1">50.4 (12.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM/Bup</td><td align="center" rowspan="1" colspan="1">0.75 (0.16)</td><td align="center" rowspan="1" colspan="1">0.65 (0.15)</td><td align="center" rowspan="1" colspan="1">1.1 (0.1)</td><td align="center" rowspan="1" colspan="1">3.3 (1.0)</td><td align="center" rowspan="1" colspan="1">2.5 (0.6)</td><td align="center" rowspan="1" colspan="1">10.9 (2.4)</td><td align="center" rowspan="1" colspan="1">6.8 (1.5)</td><td align="center" rowspan="1" colspan="1">1.6 (0.1)</td><td align="center" rowspan="1" colspan="1">14.2 (3.7)</td><td align="center" rowspan="1" colspan="1">7.2 (1.7)</td><td align="center" rowspan="1" colspan="1">10.8 (1.9)</td><td align="center" rowspan="1" colspan="1">5.7 (0.5)</td><td align="center" rowspan="1" colspan="1">31.3 (8.2)</td><td align="center" rowspan="1" colspan="1">50.5 (13.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">MDA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM</td><td align="center" rowspan="1" colspan="1">0.014 (0.006)</td><td align="center" rowspan="1" colspan="1">0.041 (0.012)</td><td align="center" rowspan="1" colspan="1">0.3 (0.1)</td><td align="center" rowspan="1" colspan="1">12.5 (8.1)</td><td align="center" rowspan="1" colspan="1">4.6 (0.8)</td><td align="center" rowspan="1" colspan="1">0.26 (0.10)</td><td align="center" rowspan="1" colspan="1">0.61 (0.19)</td><td align="center" rowspan="1" colspan="1">0.4 (0.1)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">0.76 (0.27)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">9.2 (2.3)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IM</td><td align="center" rowspan="1" colspan="1">0.011 (0.002)</td><td align="center" rowspan="1" colspan="1">0.042 (0.006)</td><td align="center" rowspan="1" colspan="1">0.3 (0.0)</td><td align="center" rowspan="1" colspan="1">18.7 (9.2)</td><td align="center" rowspan="1" colspan="1">4.4 (0.5)</td><td align="center" rowspan="1" colspan="1">0.21 (0.050)</td><td align="center" rowspan="1" colspan="1">0.65 (0.15)</td><td align="center" rowspan="1" colspan="1">0.3 (0.0)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">0.87 (0.31)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">10.6 (3.3)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM/Bup</td><td align="center" rowspan="1" colspan="1">0.010 (0.005)</td><td align="center" rowspan="1" colspan="1">0.031 (0.007)</td><td align="center" rowspan="1" colspan="1">0.3 (0.1)</td><td align="center" rowspan="1" colspan="1">14.9 (8.8)</td><td align="center" rowspan="1" colspan="1">5.2 (0.8)</td><td align="center" rowspan="1" colspan="1">0.19 (0.076)</td><td align="center" rowspan="1" colspan="1">0.49 (0.14)</td><td align="center" rowspan="1" colspan="1">0.4 (0.1)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">0.69 (0.17)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">11.1 (1.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DHMA 3S</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM</td><td align="center" rowspan="1" colspan="1">0.15 (0.080)</td><td align="center" rowspan="1" colspan="1">0.59 (0.25)</td><td align="center" rowspan="1" colspan="1">0.3 (0.1)</td><td align="center" rowspan="1" colspan="1">2.8 (1.8)</td><td align="center" rowspan="1" colspan="1">1.5 (0.3)</td><td align="center" rowspan="1" colspan="1">2.4 (1.0)</td><td align="center" rowspan="1" colspan="1">6.3 (2.7)</td><td align="center" rowspan="1" colspan="1">0.4 (0.1)</td><td align="center" rowspan="1" colspan="1">4.7 (2.5)</td><td align="center" rowspan="1" colspan="1">7.1 (3.1)</td><td align="center" rowspan="1" colspan="1">20.2 (6.2)</td><td align="center" rowspan="1" colspan="1">7.3 (1.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IM</td><td align="center" rowspan="1" colspan="1">0.055 (0.030)</td><td align="center" rowspan="1" colspan="1">0.28 (0.11)</td><td align="center" rowspan="1" colspan="1">0.2 (0.0)</td><td align="center" rowspan="1" colspan="1">1.7 (0.9)</td><td align="center" rowspan="1" colspan="1">1.9 (0.5)</td><td align="center" rowspan="1" colspan="1">0.98 (0.64)</td><td align="center" rowspan="1" colspan="1">3.0 (1.0)</td><td align="center" rowspan="1" colspan="1">0.3 (0.1)</td><td align="center" rowspan="1" colspan="1">2.6 (2.4)</td><td align="center" rowspan="1" colspan="1">3.3 (1.1)</td><td align="center" rowspan="1" colspan="1">27.4 (11.5)</td><td align="center" rowspan="1" colspan="1">7.0 (0.4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM/Bup</td><td align="center" rowspan="1" colspan="1">0.050 (0.025)</td><td align="center" rowspan="1" colspan="1">0.20 (0.088)</td><td align="center" rowspan="1" colspan="1">0.3 (0.1)</td><td align="center" rowspan="1" colspan="1">3.8 (1.1)</td><td align="center" rowspan="1" colspan="1">2.4 (0.6)</td><td align="center" rowspan="1" colspan="1">0.96 (0.44)</td><td align="center" rowspan="1" colspan="1">2.8 (1.3)</td><td align="center" rowspan="1" colspan="1">0.4 (0.1)</td><td align="center" rowspan="1" colspan="1">3.1 (2.1)</td><td align="center" rowspan="1" colspan="1">3.7 (2.1)</td><td align="center" rowspan="1" colspan="1">46.2 (32.5)</td><td align="center" rowspan="1" colspan="1">11.3 (2.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DHMA 4S</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM</td><td align="center" rowspan="1" colspan="1">0.080 (0.048)</td><td align="center" rowspan="1" colspan="1">0.055 (0.025)</td><td align="center" rowspan="1" colspan="1">1.5 (0.5)</td><td align="center" rowspan="1" colspan="1">2.0 (0.8)</td><td align="center" rowspan="1" colspan="1">1.7 (0.5)</td><td align="center" rowspan="1" colspan="1">1.3 (0.74)</td><td align="center" rowspan="1" colspan="1">0.64 (0.27)</td><td align="center" rowspan="1" colspan="1">2.0 (0.7)</td><td align="center" rowspan="1" colspan="1">2.4 (1.7)</td><td align="center" rowspan="1" colspan="1">0.80 (0.37)</td><td align="center" rowspan="1" colspan="1">17.5 (5.5)</td><td align="center" rowspan="1" colspan="1">8.1 (1.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IM</td><td align="center" rowspan="1" colspan="1">0.035 (0.005)</td><td align="center" rowspan="1" colspan="1">0.029 (0.005)</td><td align="center" rowspan="1" colspan="1">1.2 (0.1)</td><td align="center" rowspan="1" colspan="1">3.0 (1.5)</td><td align="center" rowspan="1" colspan="1">2.1 (0.5)</td><td align="center" rowspan="1" colspan="1">0.54 (0.14)</td><td align="center" rowspan="1" colspan="1">0.40 (0.11)</td><td align="center" rowspan="1" colspan="1">1.5 (0.6)</td><td align="center" rowspan="1" colspan="1">1.5 (1.0)</td><td align="center" rowspan="1" colspan="1">0.59 (0.30)</td><td align="center" rowspan="1" colspan="1">18.7 (15.6)</td><td align="center" rowspan="1" colspan="1">12.1 (5.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM/Bup</td><td align="center" rowspan="1" colspan="1">0.037 (0.015)</td><td align="center" rowspan="1" colspan="1">0.021 (0.007)</td><td align="center" rowspan="1" colspan="1">1.7 (0.6)</td><td align="center" rowspan="1" colspan="1">3.2 (1.1)</td><td align="center" rowspan="1" colspan="1">2.4 (0.9)</td><td align="center" rowspan="1" colspan="1">0.71 (0.30)</td><td align="center" rowspan="1" colspan="1">0.32 (0.11)</td><td align="center" rowspan="1" colspan="1">2.1 (0.7)</td><td align="center" rowspan="1" colspan="1">2.9 (2.2)</td><td align="center" rowspan="1" colspan="1">0.48 (0.19)</td><td align="center" rowspan="1" colspan="1">49.9 (29.3)</td><td align="center" rowspan="1" colspan="1">14.3 (3.6)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HMMA S</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM</td><td align="center" rowspan="1" colspan="1">0.37 (0.11)</td><td align="center" rowspan="1" colspan="1">0.41 (0.13)</td><td align="center" rowspan="1" colspan="1">0.9 (0.2)</td><td align="center" rowspan="1" colspan="1">2.0 (1.3)</td><td align="center" rowspan="1" colspan="1">1.6 (0.5)</td><td align="center" rowspan="1" colspan="1">5.5 (1.4)</td><td align="center" rowspan="1" colspan="1">4.2 (1.2)</td><td align="center" rowspan="1" colspan="1">1.3 (0.2)</td><td align="center" rowspan="1" colspan="1">9.6 (2.7)</td><td align="center" rowspan="1" colspan="1">4.6 (1.2)</td><td align="center" rowspan="1" colspan="1">17.5 (6.6)</td><td align="center" rowspan="1" colspan="1">6.6 (0.80)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IM</td><td align="center" rowspan="1" colspan="1">0.10 (0.041)</td><td align="center" rowspan="1" colspan="1">0.14 (0.022)</td><td align="center" rowspan="1" colspan="1">0.7 (0.2)</td><td align="center" rowspan="1" colspan="1">1.7 (0.8)</td><td align="center" rowspan="1" colspan="1">2.5 (0.3)</td><td align="center" rowspan="1" colspan="1">1.7 (0.70)</td><td align="center" rowspan="1" colspan="1">1.7 (0.30)</td><td align="center" rowspan="1" colspan="1">1.0 (0.3)</td><td align="center" rowspan="1" colspan="1">3.4 (1.3)</td><td align="center" rowspan="1" colspan="1">1.9 (0.34)</td><td align="center" rowspan="1" colspan="1">21.2 (0.40)</td><td align="center" rowspan="1" colspan="1">6.9 (0.50)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM/Bup</td><td align="center" rowspan="1" colspan="1">0.14 (0.039)</td><td align="center" rowspan="1" colspan="1">0.11 (0.033)</td><td align="center" rowspan="1" colspan="1">1.1 (0.2)</td><td align="center" rowspan="1" colspan="1">4.2 (1.1)</td><td align="center" rowspan="1" colspan="1">2.8 (0.6)</td><td align="center" rowspan="1" colspan="1">2.1 (0.67)</td><td align="center" rowspan="1" colspan="1">1.6 (0.51)</td><td align="center" rowspan="1" colspan="1">1.3 (0.4)</td><td align="center" rowspan="1" colspan="1">7.1 (4.6)</td><td align="center" rowspan="1" colspan="1">2.2 (0.75)</td><td align="center" rowspan="1" colspan="1">34.4 (23.9)</td><td align="center" rowspan="1" colspan="1">11.1 (2.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HMMA G</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM</td><td align="center" rowspan="1" colspan="1">0.21 (0.19)</td><td align="center" rowspan="1" colspan="1">0.49 (0.39)</td><td align="center" rowspan="1" colspan="1">0.5 (0.2)</td><td align="center" rowspan="1" colspan="1">3.7 (2.1)</td><td align="center" rowspan="1" colspan="1">2.9 (1.0)</td><td align="center" rowspan="1" colspan="1">3.3 (2.1)</td><td align="center" rowspan="1" colspan="1">5.2 (3.7)</td><td align="center" rowspan="1" colspan="1">0.6 (0.2)</td><td align="center" rowspan="1" colspan="1">5.5 (4.3)</td><td align="center" rowspan="1" colspan="1">5.5 (3.9)</td><td align="center" rowspan="1" colspan="1">16.0 (7.9)</td><td align="center" rowspan="1" colspan="1">6.1 (1.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IM</td><td align="center" rowspan="1" colspan="1">0.043 (0.038)</td><td align="center" rowspan="1" colspan="1">0.099 (0.060)</td><td align="center" rowspan="1" colspan="1">0.4 (0.1)</td><td align="center" rowspan="1" colspan="1">4.8 (0.5)</td><td align="center" rowspan="1" colspan="1">4.0 (0.1)</td><td align="center" rowspan="1" colspan="1">0.84 (0.74)</td><td align="center" rowspan="1" colspan="1">1.3 (0.77)</td><td align="center" rowspan="1" colspan="1">0.6 (0.2)</td><td align="center" rowspan="1" colspan="1">2.0 (1.7)</td><td align="center" rowspan="1" colspan="1">1.5 (0.83)</td><td align="center" rowspan="1" colspan="1">29.3 (12.4)</td><td align="center" rowspan="1" colspan="1">7.1 (0.4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;EM/Bup</td><td align="center" rowspan="1" colspan="1">0.049 (0.027)</td><td align="center" rowspan="1" colspan="1">0.088 (0.044)</td><td align="center" rowspan="1" colspan="1">0.6 (0.1)</td><td align="center" rowspan="1" colspan="1">7.6 (1.2)</td><td align="center" rowspan="1" colspan="1">4.9 (1.0)</td><td align="center" rowspan="1" colspan="1">0.96 (0.54)</td><td align="center" rowspan="1" colspan="1">1.3 (0.78)</td><td align="center" rowspan="1" colspan="1">0.7 (0.1)</td><td align="center" rowspan="1" colspan="1">2.3 (1.5)</td><td align="center" rowspan="1" colspan="1">1.7 (1.0)</td><td align="center" rowspan="1" colspan="1">31.7 (16.8)</td><td align="center" rowspan="1" colspan="1">9.0 (2.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><fig id="pone.0150955.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g003</object-id><label>Fig 3</label><caption><title>Plasma-concentration time profiles of MDMA and metabolites.</title><p>Plasma-concentration time profiles for <italic>R-</italic> and <italic>S-</italic>MDMA and <italic>R-</italic> and <italic>S-</italic>MDA, <italic>R-</italic> and <italic>S-</italic>DHMA 3-sulfate and <italic>R-</italic> and <italic>S-</italic>DHMA 4-sulfate, and <italic>R-</italic> and <italic>S-</italic>HMMA sulfate and <italic>R-</italic> and <italic>S-</italic>HMMA glucuronide. Black circles and solid lines represent 13 CYP2D6 extensive metabolizers (EM) after placebo-MDMA administration. Triangles and dotted lines represent three CYP2D6 intermediate metabolizers (IM) after placebo+MDMA administration. Open circles and solid lines represent 13 CYP2D6 EMs after bupropion+MDMA administration. The data are expressed as mean and SEM. *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01, ***<italic>p</italic> &#x0003c; 0.001, significant within-subject difference between placebo+MDMA and bupropion+MDMA in CYP2D6 EM subjects (Wilcoxon matched-pairs test); <sup>+</sup><italic>p</italic> &#x0003c; 0.05, <sup>++</sup><italic>p</italic> &#x0003c; 0.01, significant difference between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs (Mann-Whitney test).</p></caption><graphic xlink:href="pone.0150955.g003"/></fig><p>For MDA, C<sub>max</sub> (-27% for <italic>R</italic>-MDA, -24% for <italic>S</italic>-MDA) and AUC<sub>24</sub> values (-26% for <italic>R</italic>-MDA, -20% for <italic>S</italic>-MDA) were reduced by pretreatment with bupropion. Although <italic>R</italic>-MDA in CYP2D6 IMs showed the same effect, <italic>S</italic>-MDA in CYP2D6 IMs was within the same range as in CYP2D6 EMs. The t<sub>max</sub> and t<sub>1/2</sub> values for <italic>S</italic>-MDA were not significantly different. The t<sub>1/2</sub> for <italic>R</italic>-MDA could not be calculated because of the limited number of data points in the elimination phase.</p><p>The concentrations of all phase II metabolites significantly decreased after bupropion pretreatment compared with placebo pretreatment, with lower C<sub>max</sub> and AUC<sub>24</sub> values for <italic>R</italic>-DHMA 3-sulfate (-68% and -61%), <italic>S</italic>-DHMA 3-sulfate (-67% and -56%), <italic>R</italic>-DHMA 4-sulfate (-54% and -43%), <italic>S</italic>-DHMA 4-sulfate (-61% and -50%), <italic>R</italic>-HMMA sulfate (-62% and -62%), <italic>S</italic>-HMMA sulfate (-72% and -61%), <italic>R</italic>-HMMA glucuronide (-77% and -71%), and <italic>S</italic>-HMMA glucuronide (-82% and -74%), respectively. CYP2D6 IMs presented no significant differences compared with bupropion-treated EMs, although for <italic>S</italic>-enantiomers sulfates co-administration of bupropion apparently elevated C<sub>max</sub> while AUC<sub>24</sub> remained unaltered. The t<sub>max</sub> was reached significantly later for all phase II metabolites, varying between 40% and 100% for <italic>R</italic>-stereoisomers and between 45% and 70% for <italic>S</italic>-stereoisomers, and t<sub>1/2</sub> was prolonged up to 200% for <italic>R</italic>-stereoisomers and up to 70% for <italic>S</italic>-stereoisomers after bupropion pretreatment compared with placebo pretreatment. Similar changes were observed in CYP2D6 IMs compared with EMs, although to a much lesser extent, especially for <italic>R</italic>-stereoisomers.</p><p>The t<sub>onset</sub> was comparable between CYP2D6 EMs and IMs for all of the analytes. With bupropion pretreatment, the first detection of <italic>R</italic>-HMMA sulfate, <italic>S</italic>-HMMA sulfate, <italic>R</italic>-HMMA glucuronide, and <italic>S</italic>-HMMA glucuronide was significantly delayed (mean placebo-pretreated CYP2D6 EMs <italic>vs</italic>. bupropion-pretreated CYP2D6 EMs: 0.33 h <italic>vs</italic>. 0.53 h, 0.33 h <italic>vs</italic>. 0.56 h, 0.41 h <italic>vs</italic>. 0.73 h, and 0.38 h <italic>vs</italic>. 0.71 h, respectively).</p><p>Generally, alterations in CYP2D6 metabolism that were induced by bupropion pretreatment influenced both stereoisomers but to slightly different extents. The <italic>R/S</italic> concentration ratios over time for MDMA and all metabolites for the different treatment groups are shown in <xref ref-type="fig" rid="pone.0150955.g004">Fig 4</xref>. The MDMA <italic>R/S</italic> ratio was significantly lower after pretreatment with bupropion (-6% for C<sub>max</sub>, -9% for AUC<sub>24</sub>), as was the MDA <italic>R/S</italic> ratio (-19% for C<sub>max</sub>, -17% for AUC<sub>24</sub>). The HMMA sulfate <italic>R/S</italic> ratio was significantly higher (+21% for C<sub>max</sub>). Although CYP2D6 IMs appeared to have slightly lower mean <italic>R/S</italic> ratios than bupropion-pretreated EMs (mainly for sulfate conjugates), the trend was not significant with regard to C<sub>max</sub> and AUC<sub>24</sub> values.</p><fig id="pone.0150955.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g004</object-id><label>Fig 4</label><caption><title><italic>R/S</italic> ratios of MDMA and metabolites.</title><p><italic>R/S</italic> concentration ratios for MDMA, MDA, DHMA 3-sulfate, DHMA 4-sulfate, HMMA sulfate, and HMMA glucuronide over time. Black circles and solid lines represent 13 CYP2D6 extensive metabolizers (EM). Triangles and dotted lines represent three CYP2D6 intermediate metabolizers (IM). Open circles and solid lines represent 13 CYP2D6 EMs after pretreatment with bupropion. The data are expressed as mean and SEM. *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01, ***<italic>p</italic> &#x0003c; 0.001, significant within-subject difference between placebo+MDMA and bupropion+MDMA in CYP2D6 EM subjects (Wilcoxon matched-pairs test); <sup>+</sup><italic>p</italic> &#x0003c; 0.05, <sup>++</sup><italic>p</italic> &#x0003c; 0.01, significant differences between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs (Mann-Whitney test).</p></caption><graphic xlink:href="pone.0150955.g004"/></fig><p>Metabolite/MDMA ratios at each time point for CYP2D6 EMs, IMs, and bupropion-pretreated EMs are shown in <xref ref-type="fig" rid="pone.0150955.g005">Fig 5a</xref>, exemplified by the <italic>R</italic>-DHMA 3-sulfate/<italic>R</italic>-MDMA ratio. Significant differences were observed between CYP2D6 EMs and IMs and between placebo-pretreated EMs and bupropion-pretreated EMs, whereas IMs and bupropion-pretreated EMs did not differ significantly. The same was observed for all of the other metabolites. Despite significant differences between means, the ranges considerably overlapped. <xref ref-type="fig" rid="pone.0150955.g005">Fig 5b</xref> shows the changes in metabolite/MDMA ratios over time, with the highest values (mean: 9.9 in placebo-pretreated EMs, 1.9 in IMs, and 0.4 in bupropion-pretreated EMs) in the first hour after MDMA administration, decreasing to rather constant values after approximately 2 h (mean: 0.22 in placebo-pretreated EMs, 0.10 in IMs, 0.10 in bupropion-pretreated EMs). The initial high ratios were not observed after bupropion-pretreatment. Similar changes in metabolite/MDMA ratios were observed for all of the other metabolites, with the following mean initial and constant ratios, respectively: <italic>S</italic>-DHMA 3-sulfate (33 and 1.1 in placebo-pretreated EMs, 8.8 and 0.42 in IMs, and 1.8 and 0.34 in bupropion-pretreated EMs), <italic>R</italic>-DHMA 4-sulfate (4.9 and 0.13 in placebo-pretreated EMs, 0.94 and 0.05 in IMs, and 0.89 and 0.05 in bupropion-pretreated EMs), <italic>S</italic>-DHMA 4-sulfate (3.8 and 0.11 in placebo-pretreated EMs, 0.91 and 0.05 in IMs, and 0.60 and 0.04 in bupropion-pretreated EMs), <italic>R</italic>-HMMA sulfate (15.8 and 0.54 in placebo-pretreated EMs, 1.9 and 0.13 in IMs, and 0.31 and 0.13 in bupropion-pretreated EMs), <italic>S</italic>-HMMA sulfate (17.7 and 0.86 in placebo-pretreated EMs, 2.3 and 0.28 in IMs, and 0.26 and 0.21 in bupropion-pretreated EMs), <italic>R</italic>-HMMA glucuronide (1.3 and 0.40 in placebo-pretreated EMs, 0.05 and 0.05 in IMs, and 0.09 and 0.05 in bupropion-pretreated EMs), and <italic>S</italic>-HMMA glucuronide (5.6 and 1.3 in placebo-pretreated EMs, 0.30 and 0.20 in IMs, and 0.10 and 0.20 in bupropion-pretreated EMs).</p><fig id="pone.0150955.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g005</object-id><label>Fig 5</label><caption><title>Metabolite ratios.</title><p>(a) Metabolite ratio of <italic>R</italic>-DHMA 3-sulfate to <italic>R</italic>-MDMA in placebo-pretreated CYP2D6 extensive metabolizers (EM), intermediate metabolizers (IM), and EMs after pretreatment with bupropion. The data represent single measurements of 13 participants (placebo-pretreated EMs and bupropion-pretreated EMs) or three IMs at different time points after MDMA administration (0.33&#x02013;24 h). <sup>+++</sup><italic>p</italic> &#x0003c; 0.001, significant difference between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs (Mann-Whitney test). (b) Metabolite ratio of <italic>R</italic>-DHMA 3-sulfate to <italic>R</italic>-MDMA in CYP2D6 EMs, IMs, and EMs after pretreatment with bupropion over time. Black circles and solid lines represent extensive metabolizers (EM). Triangles and dotted lines represent intermediate metabolizers (IM). Open circles and solid lines represent EMs after pretreatment with bupropion. The data are expressed as mean and SEM.</p></caption><graphic xlink:href="pone.0150955.g005"/></fig><p>The AUC<sub>24</sub> metabolite ratios of all CYP2D6-mediated metabolites (<italic>R</italic>,<italic>S</italic>-DHMA 3-sulfate, <italic>R</italic>,<italic>S</italic>-DHMA 4-sulfate, <italic>R</italic>,<italic>S</italic>-HMMA sulfate, and <italic>R</italic>,<italic>S-</italic>HMMA glucuronide) to <italic>R/S</italic>-MDMA were significantly different between placebo-pretreated CYP2D6 EMs and IMs and between placebo-pretreated EMs and bupropion-pretreated EMs but not between IMs and bupropion-pretreated EMs (<xref ref-type="fig" rid="pone.0150955.g006">Fig 6</xref>). The same result was found for the AUC<sub>24</sub> ratio between each single stereoisomer and MDMA.</p><fig id="pone.0150955.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g006</object-id><label>Fig 6</label><caption><title>Influence of CYP2D6 genotype on MDMA metabolite formation.</title><p>Correlations between CYP2D6 genotype (extensive metabolizers [EM], intermediate metabolizers [IM], and bupropion-pretreated EMs) and AUC<sub>24</sub> ratio of the sum of CYP2D6-dependently formed metabolites (DHMA 3-sulfate, DHMA 4-sulfate, HMMA sulfate, and HMMA glucuronide) to MDMA. The data represent individual participants (EM, <italic>n</italic> = 13; IM, <italic>n</italic> = 3; EMs after bupropion pretreatment, <italic>n</italic> = 13). *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c;0.01, ***<italic>p</italic> &#x0003c; 0.001, significant difference between EMs and bupropion-pretreated EMs (Wilcoxon matched-pairs test); <sup>+</sup><italic>p</italic> &#x0003c; 0.05, <sup>++</sup><italic>p</italic> &#x0003c; 0.01, significant difference between bupropion-pretreated EMs and IMs (Mann-Whitney test).</p></caption><graphic xlink:href="pone.0150955.g006"/></fig></sec><sec id="sec010"><title>Chiral pharmacokinetic analysis of bupropion and hydroxybupropion</title><p>Chiral separation was achieved on a chiral AGP column with sufficient separation of each stereoisomer. The respective chromatogram is provided in the Supporting Information (<xref ref-type="supplementary-material" rid="pone.0150955.s001">S1 Fig</xref>). The results for recovery, matrix effects, bias, and imprecision are provided in the Supporting Information (<xref ref-type="supplementary-material" rid="pone.0150955.s003">S1 Table</xref>). The method was sensitive and selective and showed a linear correlation for each bupropion enantiomer (from 0.5 to 200 ng/ml) and for the two hydroxybupropion stereoisomers (from 2.5 to 1000 ng/ml).</p><p>Mean plasma concentration-time profiles for <italic>R</italic>- and <italic>S</italic>-bupropion and <italic>R</italic>,<italic>R</italic>- and <italic>S</italic>,<italic>S</italic>-hydroxybupropion after placebo and MDMA co-administration are shown in <xref ref-type="fig" rid="pone.0150955.g007">Fig 7</xref>, respectively. The calculated pharmacokinetic parameters are listed in <xref ref-type="table" rid="pone.0150955.t002">Table 2</xref>. MDMA co-administration did not significantly alter the concentrations of either <italic>R</italic>- and <italic>S</italic>-bupropion or <italic>R</italic>,<italic>R</italic>- and <italic>S</italic>,<italic>S</italic>-hydroxybupropion.</p><table-wrap id="pone.0150955.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.t002</object-id><label>Table 2</label><caption><title>Pharmacokinetic data of Bupropion (P placebo, M MDMA).</title></caption><alternatives><graphic id="pone.0150955.t002g" xlink:href="pone.0150955.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Genotype CYP2B6</th><th align="center" colspan="2" rowspan="1">C<sub>max</sub> [ng/ml]</th><th align="center" colspan="2" rowspan="1">t<sub>max</sub> [h]</th><th align="center" colspan="2" rowspan="1">AUC0-24h [ng/ml*h-1]</th><th align="center" colspan="2" rowspan="1">AUCtotal [ng/ml*h-1]</th><th align="center" colspan="2" rowspan="1">t1/2 [h]</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>R/ R</italic>,<italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S/ S</italic>,<italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R/ R</italic>,<italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S/ S</italic>,<italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R/ R</italic>,<italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S/ S</italic>,<italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R/ R</italic>,<italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S/ S</italic>,<italic>S</italic></th><th align="center" rowspan="1" colspan="1"><italic>R/ R</italic>,<italic>R</italic></th><th align="center" rowspan="1" colspan="1"><italic>S/ S</italic>,<italic>S</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bupropion</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;P</td><td align="center" rowspan="1" colspan="1">normal</td><td align="center" rowspan="1" colspan="1">51.2 (6.0)</td><td align="center" rowspan="1" colspan="1">22.8 (12.3)</td><td align="center" rowspan="1" colspan="1">5.0 (2.1)</td><td align="center" rowspan="1" colspan="1">5.0 (1.4)</td><td align="center" rowspan="1" colspan="1">807 (387)</td><td align="center" rowspan="1" colspan="1">346 (172)</td><td align="center" rowspan="1" colspan="1">942 (444)</td><td align="center" rowspan="1" colspan="1">390 (186)</td><td align="center" rowspan="1" colspan="1">8.4 (1.8)</td><td align="center" rowspan="1" colspan="1">7.3 (1.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;P</td><td align="center" rowspan="1" colspan="1">reduced</td><td align="center" rowspan="1" colspan="1">68.0 (15.6)</td><td align="center" rowspan="1" colspan="1">28.6 (3.8)</td><td align="center" rowspan="1" colspan="1">5.8 (2.5)</td><td align="center" rowspan="1" colspan="1">5.2 (0.6)</td><td align="center" rowspan="1" colspan="1">1099 (112)</td><td align="center" rowspan="1" colspan="1">442 (52.6)</td><td align="center" rowspan="1" colspan="1">1334 (253)</td><td align="center" rowspan="1" colspan="1">518 (110)</td><td align="center" rowspan="1" colspan="1">8.9 (2.9)</td><td align="center" rowspan="1" colspan="1">7.8 (2.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;M</td><td align="center" rowspan="1" colspan="1">normal</td><td align="center" rowspan="1" colspan="1">53.5 (19.4)</td><td align="center" rowspan="1" colspan="1">21.9 (6.7)</td><td align="center" rowspan="1" colspan="1">5.2 (2.6)</td><td align="center" rowspan="1" colspan="1">6.2 (2.4)</td><td align="center" rowspan="1" colspan="1">822 (237)</td><td align="center" rowspan="1" colspan="1">344 (75.1)</td><td align="center" rowspan="1" colspan="1">969 (284)</td><td align="center" rowspan="1" colspan="1">395 (109)</td><td align="center" rowspan="1" colspan="1">8.5 (3.3)</td><td align="center" rowspan="1" colspan="1">7.5 (2.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;M</td><td align="center" rowspan="1" colspan="1">reduced</td><td align="center" rowspan="1" colspan="1">68.7 (23.6)</td><td align="center" rowspan="1" colspan="1">31.4 (17.0)</td><td align="center" rowspan="1" colspan="1">5.6 (2.3)</td><td align="center" rowspan="1" colspan="1">4.7 (1.3)</td><td align="center" rowspan="1" colspan="1">1139 (551)</td><td align="center" rowspan="1" colspan="1">469 (290)</td><td align="center" rowspan="1" colspan="1">1313 (669)</td><td align="center" rowspan="1" colspan="1">533 (339)</td><td align="center" rowspan="1" colspan="1">7.5 (1.7)</td><td align="center" rowspan="1" colspan="1">6.8 (1.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">HO-Bupropion</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;P</td><td align="center" rowspan="1" colspan="1">normal</td><td align="center" rowspan="1" colspan="1">542 (145)</td><td align="center" rowspan="1" colspan="1">26.7 (2.6)</td><td align="center" rowspan="1" colspan="1">12.3 (5.2)</td><td align="center" rowspan="1" colspan="1">8.4 (1.7)</td><td align="center" rowspan="1" colspan="1">13778 (4205)</td><td align="center" rowspan="1" colspan="1">567 (81.7)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;P</td><td align="center" rowspan="1" colspan="1">reduced</td><td align="center" rowspan="1" colspan="1">358 (53.3)</td><td align="center" rowspan="1" colspan="1">18.6 (6.2)</td><td align="center" rowspan="1" colspan="1">16.9 (7.6)</td><td align="center" rowspan="1" colspan="1">9.6 (3.3)</td><td align="center" rowspan="1" colspan="1">9082 (1685)</td><td align="center" rowspan="1" colspan="1">417 (131)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;M</td><td align="center" rowspan="1" colspan="1">normal</td><td align="center" rowspan="1" colspan="1">479 (180)</td><td align="center" rowspan="1" colspan="1">29.4 (13.6)</td><td align="center" rowspan="1" colspan="1">13.0 (7.2)</td><td align="center" rowspan="1" colspan="1">7.8 (2.7)</td><td align="center" rowspan="1" colspan="1">11692 (3122)</td><td align="center" rowspan="1" colspan="1">521 (187)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;M</td><td align="center" rowspan="1" colspan="1">reduced</td><td align="center" rowspan="1" colspan="1">452 (180)</td><td align="center" rowspan="1" colspan="1">29.6 (10.0)</td><td align="center" rowspan="1" colspan="1">11.7 (4.6)</td><td align="center" rowspan="1" colspan="1">8.5 (1.4)</td><td align="center" rowspan="1" colspan="1">10527 (5561)</td><td align="center" rowspan="1" colspan="1">626 (212)</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td><td align="center" rowspan="1" colspan="1">n.d.</td></tr></tbody></table></alternatives></table-wrap><fig id="pone.0150955.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0150955.g007</object-id><label>Fig 7</label><caption><title>Chiral plasma-concentration time profiles for bupropion and hydroxybupropion.</title><p>Plasma-concentration time profiles for <italic>R</italic>- and <italic>S</italic>-bupropion (A) and <italic>R</italic>,<italic>R</italic>- and <italic>S</italic>,<italic>S-</italic>hydroxybupropion (B) after co-administration of placebo (black) or MDMA (white). Circles represent <italic>R</italic>- and <italic>R</italic>,<italic>R</italic>-stereoisomers. Triangles represent <italic>S</italic>- and <italic>S</italic>,<italic>S</italic>-stereoisomers. The data are expressed as mean and SEM (<italic>n</italic> = 16 participants). Differences between placebo and MDMA were not statistically significant.</p></caption><graphic xlink:href="pone.0150955.g007"/></fig></sec></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>The co-administration of CYP2D6 inhibitors was used to mimic an IM or PM genotype, which is a feasible approach to study the influence of CYP2D6 on MDMA metabolism. Previous studies used paroxetine as a CYP2D6 inhibitor in seven EMs who were orally administered MDMA [<xref rid="pone.0150955.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0150955.ref051" ref-type="bibr">51</xref>]. However, the analysis was only performed with racemic MDMA and free metabolites after conjugate cleavage. As not only stereoselectivity of MDMA itself, but also of its primary metabolite DHMA is discussed in terms of (neuro-)toxicity [<xref rid="pone.0150955.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0150955.ref053" ref-type="bibr">53</xref>] the further metabolic fate of free DHMA and its resulting stereoselectivities is of interest. Stereoselectivity is not only obtained from initial formation but rather influenced by follow-up metabolic steps such as phase II metabolism. Furthermore, recent studies discussed DHMA to play a role in acute cardiovascular effects observed after MDMA consumption [<xref rid="pone.0150955.ref054" ref-type="bibr">54</xref>]. It was shown that the initial CYP2D6 metabolite DHMA is not present in human plasma in its free form but rather as its sulfate conjugates [<xref rid="pone.0150955.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0150955.ref055" ref-type="bibr">55</xref>], thus making meaningful interpretations of the impact of CYP2D6 difficult because at least one additional metabolic step occurs. Such an analysis after conjugate cleavage will not represent the actual abundance of all metabolites that are present in plasma, thus complicating correlations with potential neurotoxicity. Furthermore, CYP2D6 inhibition might result in higher activity of other CYP enzymes with different stereoselectivity, leading to differences in <italic>R</italic>- and <italic>S</italic>-MDMA and consequently different pharmacodynamic effects and acute toxicity [<xref rid="pone.0150955.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0150955.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0150955.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0150955.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0150955.ref056" ref-type="bibr">56</xref>]. Therefore, the present study sought to elucidate the effects of bupropion in mimicking a reduction of CYP2D6 activity in humans and its influence on the metabolism and pharmacokinetics of MDMA in a stereoselective manner and after direct analysis of the conjugates. Although from the pharmacological and toxicological point of view no relevant toxicity is expected from the phase II metabolites as terminal metabolites, their (stereoselective) formation should majorly influence the concentration and stereoselectivity of the active metabolite DHMA. Bupropion similarly inhibited CYP2D6 as paroxetine and fluoxetine <italic>in vivo</italic>, but it is not a substrate of CYP2D6 [<xref rid="pone.0150955.ref044" ref-type="bibr">44</xref>]. The data could then be compared for different genotypes of CYP2D6 (EM and IM).</p><p>We found that the pharmacokinetics of MDMA and MDA enantiomers in EMs were comparable to those published in other studies [<xref rid="pone.0150955.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0150955.ref057" ref-type="bibr">57</xref>].</p><p>Bupropion increased <italic>R</italic>- and <italic>S</italic>-MDMA C<sub>max</sub> and AUC<sub>24</sub> values in CYP2D6 EMs resulting in exposure to MDMA in the same range as previously described for racemic MDMA in one PM [<xref rid="pone.0150955.ref058" ref-type="bibr">58</xref>] and after CYP2D6 inhibition with paroxetine [<xref rid="pone.0150955.ref039" ref-type="bibr">39</xref>]. The t<sub>max</sub> and t<sub>onset</sub> of both enantiomers were unaltered by bupropion, whereas t<sub>1/2</sub> was prolonged and plasma clearance was reduced, suggesting that the metabolic interaction was responsible for differences in pharmacokinetics rather than absorption and/or distribution, which is again consistent with other studies [<xref rid="pone.0150955.ref039" ref-type="bibr">39</xref>].</p><p><italic>R-</italic> and <italic>S-</italic>MDA C<sub>max</sub> and AUC<sub>24</sub> values were decreased by the co-administration of bupropion. MDA is mainly formed through CYP2B6, with bupropion as a CYP2B6 substrate [<xref rid="pone.0150955.ref059" ref-type="bibr">59</xref>] that acts as a competitive inhibitor in this pathway. In CYP2D6 IMs, <italic>S-</italic>MDA levels were not significantly different from EMs with regard to either C<sub>max</sub> or AUC<sub>24</sub> (<xref ref-type="fig" rid="pone.0150955.g001">Fig 1A</xref>). This indicates the competitive inhibition of CYP2B6 by bupropion. Segura et al. reported an opposite effect with racemic MDA, in which C<sub>max</sub> and AUC levels increased, thus suggesting accumulation through the inhibition of subsequent MDA pathways by CYP2D6 [<xref rid="pone.0150955.ref039" ref-type="bibr">39</xref>].</p><p>As expected, the co-administration of bupropion and MDMA decreased all metabolites that are formed CYP2D6-dependently. Although the extent of CYP2D6-inhibition by bupropion on C<sub>max</sub> and AUC<sub>24</sub> values was comparable for <italic>R</italic>- and <italic>S</italic>-DHMA, 3-sulfate, <italic>R-/S-</italic>DHMA 4-sulfate, and <italic>R-/S-</italic>HMMA sulfate, the reduction of <italic>S</italic>-HMMA glucuronide was significantly greater. UGTs are enzymes with low affinity for their substrates but high capacity, whereas SULTs have high affinity for their substrates but are easily saturated. If lower concentrations of HMMA are present as a consequence of a decrease in the CYP2D6-dependent formation of DHMA and consequently HMMA, then the higher affinity of SULT should be more relevant than the higher capacity of UGTs. Furthermore, UGT inhibition by bupropion might occur [<xref rid="pone.0150955.ref060" ref-type="bibr">60</xref>]. Although no significant differences in C<sub>max</sub> and AUC<sub>24</sub> were found between the bupropion-pretreated CYP2D6 EMs and placebo-pretreated IMs, the <italic>S</italic>-enantiomer C<sub>max</sub> of sulfate metabolites appeared to be lower after bupropion pretreatment in EMs compared with IMs who were pretreated with placebo. This effect was not observed for HMMA glucuronide. Notably, the present study only included three IMs. The statistical power, therefore, was rather low, and true differences might have gone undetected. The t<sub>max</sub> of all of the conjugates and t<sub>onset</sub> for <italic>R</italic>- and <italic>S</italic>-HMMA sulfate and <italic>R</italic>- and <italic>S</italic>-HMMA glucuronide were reached significantly later with bupropion compared with placebo pretreatment, which could be congruent with lower first-pass metabolism. Additionally, t<sub>1/2</sub> was substantially prolonged after bupropion pretreatment compared with placebo pretreatment, but it was not significantly different between CYP2D6 IMs and EMs. This suggests that other than CYP2D6-mediated interactions might be involved.</p><p>Other CYP enzymes might compensate for the decrease in CYP2D6 activity, and different <italic>R-</italic> and <italic>S-</italic> stereoisomer concentrations and thus pharmacological effects might occur due to different potencies of enantiomers[<xref rid="pone.0150955.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0150955.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0150955.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0150955.ref053" ref-type="bibr">53</xref>]. For MDMA, significant reductions of <italic>R/S</italic> ratios were observed between placebo-pretreated CYP2D6 EMs and bupropion-pretreated EMs but not between placebo-pretreated CYP2D6 IMs and bupropion-pretreated EMs over 24 h (<xref ref-type="fig" rid="pone.0150955.g004">Fig 4</xref>). CYP2D6 preferentially demethylenates <italic>S-</italic>MDMA, and the inhibitory effect should be more dominant on that enantiomer, resulting in higher concentrations of the pharmacologically more active <italic>S</italic>-MDMA through a reduction of metabolism. The inhibition of CYP2D6 is likely to result in the loss of metabolic enantioselectivity because other enzymes do not provide comparable stereoselectivity as CYP2D6 [<xref rid="pone.0150955.ref026" ref-type="bibr">26</xref>]. However, the observed mean overall effect on MDMA <italic>R/S</italic> ratios was less than 10%. MDA showed the same effect, likely because of inhibition of its metabolism by CYP2D6, which is identical to MDMA. Importantly, MDMA is a CYP2D6 inhibitor [<xref rid="pone.0150955.ref061" ref-type="bibr">61</xref>], and only one high dose of MDMA was administered, similar to a previous study [<xref rid="pone.0150955.ref039" ref-type="bibr">39</xref>]. Phase II metabolites represent secondary or even tertiary metabolites that involve further enzymes. Generally, t<sub>1/2</sub> values for <italic>R</italic>-enantiomers were higher than for <italic>S-</italic>stereoisomers [<xref rid="pone.0150955.ref023" ref-type="bibr">23</xref>]. After pretreatment with bupropion, the prolongation of t<sub>1/2</sub> for <italic>R</italic>-conjugates was even higher than for <italic>S-</italic>enantiomers.</p><p>High interindividual variations in plasma concentrations of MDMA and its metabolites have been reported [<xref rid="pone.0150955.ref023" ref-type="bibr">23</xref>]. The questions how CYP2D6 genotypes or CYP2D6 inhibition alter concentrations of MDMA [<xref rid="pone.0150955.ref061" ref-type="bibr">61</xref>&#x02013;<xref rid="pone.0150955.ref063" ref-type="bibr">63</xref>] is of interest in clinical and forensic toxicology. Different approaches were considered in the present study to address this question. For <italic>R/S</italic> ratios, only slight differences between CYP2D6 EMs, IMs, and bupropion-pretreated EMs were observed. In contrast, significant differences were found for metabolite ratios of CYP2D6-dependetly formed metabolites to MDMA between groups (<xref ref-type="fig" rid="pone.0150955.g005">Fig 5a</xref>, exemplified by the <italic>R-</italic>DHMA 3-sulfate/<italic>R</italic>-MDMA ratio). However, large variations depending on the time post MDMA dose (<xref ref-type="fig" rid="pone.0150955.g005">Fig 5b</xref>) were observed limiting the value of these ratios as useful estimation of CYP2D6 function without knowledge of last MDMA intake in forensic cases. For all conjugates, initial high values were observed in CYP2D6 EMs, which can be explained by rapidly occurring first-pass metabolism. This effect was nearly completely lost in CYP2D6 IMs and after co-administration of the CYP2D6 inhibitor bupropion, which is consistent with lower first-pass metabolism. Oftentimes, correlations between genotypes and phenotypes are based on AUC values or AUC ratios between metabolites and/or parent compounds. However, in these studies, multiple blood samples and full pharmacokinetic analysis are necessary. Nevertheless, AUC<sub>24</sub> ratios between MDMA conjugates and MDMA correlated well with CYP2D6 genotype and bupropion-inhibited phenotype (<xref ref-type="fig" rid="pone.0150955.g006">Fig 6</xref>).</p><p>Bupropion and its main metabolite hydroxybupropion were analyzed stereoselectively in the present study to determine the effect of MDMA on bupropion`s complex and stereoselective metabolism and possible correlations with CYP2D6 inhibition. The minor dehydrometabolite was previously determined in a pharmacodynamics study [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>] and thus not included in the present study. The t<sub>1/2</sub> of hydroxybupropion diastereomers could not be determined because of slow elimination and the limited blood sampling time of only 24 h. Plasma concentration-time profiles were comparable to those in previous studies after a single bupropion dose [<xref rid="pone.0150955.ref043" ref-type="bibr">43</xref>]. No stereoisomer of bupropion or hydroxybupropion was significantly different between the bupropion-placebo and bupropion-MDMA groups (<xref ref-type="fig" rid="pone.0150955.g007">Fig 7</xref>), indicating that the CYP2D6 inhibitor MDMA had no influence on bupropion metabolism. This was expected because bupropion is primarily hydroxylated by CYP2B6 [<xref rid="pone.0150955.ref059" ref-type="bibr">59</xref>]. Although MDMA is also partially cleared by CYP2B6 to MDA, this only represents a minor pathway and is somewhat in contrast to a previous racemic analysis of the same samples, showing increases in both bupropion and hydroxybupropion through MDMA. However, the observed effect could not be fully explained [<xref rid="pone.0150955.ref040" ref-type="bibr">40</xref>] and was not reproducible in the chiral reanalysis.</p><p>No correlation was found between <italic>R-</italic> or <italic>S-</italic>bupropion concentrations and the CYP2D6-dependently formed MDMA metabolites. Previous studies suggested that bupropion&#x02019;s metabolites (mainly dehydrobupropion) rather than bupropion itself act as CYP2D6 inhibitors [<xref rid="pone.0150955.ref045" ref-type="bibr">45</xref>]. However, comparisons of <italic>R</italic>,<italic>R</italic>-hydroxybupropion, <italic>S</italic>,<italic>S</italic>-hydroxybupropion, and dehydrobupropion did not show such a relationship.</p></sec><sec sec-type="conclusions" id="sec012"><title>Conclusion</title><p>The CYP2D6 inhibitor bupropion altered the chiral pharmacokinetics of MDMA. Although interactions other than the metabolic inhibition of CYP2D6 seem to occur, generally good agreement was found between the effects of genetically impaired CYP2D6 function (EMs <italic>vs</italic>. IMs) and the effects of pharmacological CYP2D6 inhibition (placebo <italic>vs</italic>. bupropion-pretreated EMs) on the metabolism of MDMA. CYP2D6 function modulated exposure to MDMA <italic>R</italic>- and <italic>S-</italic>enantiomers, but the clinical implications of this pharmacokinetic interaction remain to be determined. The present pharmacokinetic data might aid in further interpretations of toxicity and neurotoxicity based on CYP2D6-dependent MDMA metabolism and resulting stereoselective concentrations.</p></sec><sec sec-type="supplementary-material" id="sec013"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0150955.s001"><label>S1 Fig</label><caption><title>Chiral LC-MS/MS analysis of bupropion and hydroxybupropion.</title><p>MRM chromatogram of the chiral analysis of bupropion and hydroxybupropion on a Chiral AGP column. Depicted are the quantifier MRM chromatograms of R/S-bupropion and R,R-/S,S-hydroxybupropion of a QC med sample.</p><p>(TIF)</p></caption><media xlink:href="pone.0150955.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0150955.s002"><label>S2 Fig</label><caption><title>Consort flow chart.</title><p>Flow diagram of the progress through the phases of the randomized clinical trial including enrolment, intervention allocation, follow-up, and data analysis.</p><p>(PPT)</p></caption><media xlink:href="pone.0150955.s002.ppt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0150955.s003"><label>S1 Table</label><caption><title>Validation data.</title><p>Validation data for chiral bupropion analysis, RE: recovery; CV: coefficient of variation; ME: matrix effect; IS: internal standard; RSDR: intraday precision; RSDT: interday precision; QC: quality control.</p><p>(DOCX)</p></caption><media xlink:href="pone.0150955.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0150955.s004"><label>S1 Text</label><caption><title>Chiral analysis of bupropion and hydroxybupropion.</title><p>(DOCX)</p></caption><media xlink:href="pone.0150955.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0150955.s005"><label>S2 Text</label><caption><title>Study protocol.</title><p>(PDF)</p></caption><media xlink:href="pone.0150955.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank PD Dr. Frank T. Peters and Dr. Michael Poetzsch for their helpful support and discussions and express their gratitude to Emma Louise Kessler, MD for her generous legacy she donated to the Institute of Forensic Medicine at the University of Zurich, Switzerland for research purposes.</p></ack><ref-list><title>References</title><ref id="pone.0150955.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Hysek</surname><given-names>CM</given-names></name>, <name><surname>Schmid</surname><given-names>Y</given-names></name>, <name><surname>Simmler</surname><given-names>LD</given-names></name>, <name><surname>Domes</surname><given-names>G</given-names></name>, <name><surname>Heinrichs</surname><given-names>M</given-names></name>, <name><surname>Eisenegger</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>MDMA enhances emotional empathy and prosocial behavior</article-title>. <source>Soc Cogn Affect Neurosci</source>. <year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1645</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/scan/nst161">10.1093/scan/nst161</ext-link></comment>
<pub-id pub-id-type="pmid">24097374</pub-id></mixed-citation></ref><ref id="pone.0150955.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Rietjens</surname><given-names>SJ</given-names></name>, <name><surname>Hondebrink</surname><given-names>L</given-names></name>, <name><surname>Westerink</surname><given-names>RH</given-names></name>, <name><surname>Meulenbelt</surname><given-names>J</given-names></name>. <article-title>Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions</article-title>. <source>Crit Rev Toxicol</source>. <year>2012</year>;<volume>42</volume>(<issue>10</issue>):<fpage>854</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/10408444.2012.725029">10.3109/10408444.2012.725029</ext-link></comment>
<pub-id pub-id-type="pmid">23030234</pub-id></mixed-citation></ref><ref id="pone.0150955.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Schechter</surname><given-names>MD</given-names></name>. <article-title>MDMA as a discriminative stimulus: isomeric comparisons</article-title>. <source>Pharmacol Biochem Behav</source>. <year>1987</year>;<volume>27</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="pmid">2886996</pub-id></mixed-citation></ref><ref id="pone.0150955.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>MP</given-names></name>, <name><surname>Hoffman</surname><given-names>AJ</given-names></name>, <name><surname>Nichols</surname><given-names>DE</given-names></name>. <article-title>Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices</article-title>. <source>Eur J Pharmacol</source>. <year>1986</year>;<volume>132</volume>(<issue>2&#x02013;3</issue>):<fpage>269</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="pmid">2880735</pub-id></mixed-citation></ref><ref id="pone.0150955.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Hiramatsu</surname><given-names>M</given-names></name>, <name><surname>Cho</surname><given-names>AK</given-names></name>. <article-title>Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study</article-title>. <source>Neuropharmacology</source>. <year>1990</year>;<volume>29</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="pmid">1691459</pub-id></mixed-citation></ref><ref id="pone.0150955.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>McKenna</surname><given-names>DJ</given-names></name>, <name><surname>Guan</surname><given-names>XM</given-names></name>, <name><surname>Shulgin</surname><given-names>AT</given-names></name>. <article-title>3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine</article-title>. <source>Pharmacol Biochem Behav</source>. <year>1991</year>;<volume>38</volume>(<issue>3</issue>):<fpage>505</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="pmid">1829838</pub-id></mixed-citation></ref><ref id="pone.0150955.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Glennon</surname><given-names>RA</given-names></name>, <name><surname>Yousif</surname><given-names>M</given-names></name>, <name><surname>Patrick</surname><given-names>G</given-names></name>. <article-title>Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs</article-title>. <source>Pharmacol Biochem Behav</source>. <year>1988</year>;<volume>29</volume>(<issue>3</issue>):<fpage>443</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">2896360</pub-id></mixed-citation></ref><ref id="pone.0150955.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>LE</given-names></name>, <name><surname>Taylor</surname><given-names>MM</given-names></name>. <article-title>Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination</article-title>. <source>Pharmacol Biochem Behav</source>. <year>1997</year>;<volume>57</volume>(<issue>4</issue>):<fpage>737</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="pmid">9259001</pub-id></mixed-citation></ref><ref id="pone.0150955.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Kalant</surname><given-names>H</given-names></name>. <article-title>The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs</article-title>. <source>Can Med Assoc J</source>. <year>2001</year>;<volume>165</volume>(<issue>7</issue>):<fpage>917</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">11599334</pub-id></mixed-citation></ref><ref id="pone.0150955.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>JR</given-names></name>, <name><surname>Hayes</surname><given-names>JA</given-names></name>, <name><surname>deSouza</surname><given-names>IS</given-names></name>, <name><surname>Marker</surname><given-names>E</given-names></name>, <name><surname>Stajic</surname><given-names>M</given-names></name>. <article-title>Ecstasy (MDMA) deaths in New York City: a case series and review of the literature</article-title>. <source>J Forensic Sci</source>. <year>2002</year>;<volume>47</volume>(<issue>1</issue>):<fpage>121</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="pmid">12064638</pub-id></mixed-citation></ref><ref id="pone.0150955.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Esteban</surname><given-names>B</given-names></name>, <name><surname>O'Shea</surname><given-names>E</given-names></name>, <name><surname>Camarero</surname><given-names>J</given-names></name>, <name><surname>Sanchez</surname><given-names>V</given-names></name>, <name><surname>Green</surname><given-names>AR</given-names></name>, <name><surname>Colado</surname><given-names>MI</given-names></name>. <article-title>3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2001</year>;<volume>154</volume>(<issue>3</issue>):<fpage>251</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">11351932</pub-id></mixed-citation></ref><ref id="pone.0150955.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Bai</surname><given-names>F</given-names></name>, <name><surname>Lau</surname><given-names>SS</given-names></name>, <name><surname>Monks</surname><given-names>TJ</given-names></name>. <article-title>Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity</article-title>. <source>Chem Res Toxicol</source>. <year>1999</year>;<volume>12</volume>(<issue>12</issue>):<fpage>1150</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">10604863</pub-id></mixed-citation></ref><ref id="pone.0150955.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Hiramatsu</surname><given-names>M</given-names></name>, <name><surname>Kumagai</surname><given-names>Y</given-names></name>, <name><surname>Unger</surname><given-names>SE</given-names></name>, <name><surname>Cho</surname><given-names>AK</given-names></name>. <article-title>Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1990</year>;<volume>254</volume>:<fpage>521</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">1974641</pub-id></mixed-citation></ref><ref id="pone.0150955.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>RT</given-names></name>, <name><surname>Lau</surname><given-names>SS</given-names></name>, <name><surname>Monks</surname><given-names>TJ</given-names></name>. <article-title>2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</article-title>. <source>Eur J Pharmacol</source>. <year>1997</year>;<volume>323</volume>:<fpage>173</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="pmid">9128836</pub-id></mixed-citation></ref><ref id="pone.0150955.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Mueller</surname><given-names>M</given-names></name>, <name><surname>Yuan</surname><given-names>J</given-names></name>, <name><surname>Felim</surname><given-names>A</given-names></name>, <name><surname>Neudorffer</surname><given-names>A</given-names></name>, <name><surname>Peters</surname><given-names>FT</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>, <etal>et al</etal>
<article-title>Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity</article-title>. <source>Drug Metab Dispos</source>. <year>2009</year>;<volume>37</volume>(<issue>10</issue>):<fpage>2079</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.109.028340">10.1124/dmd.109.028340</ext-link></comment>
<pub-id pub-id-type="pmid">19628751</pub-id></mixed-citation></ref><ref id="pone.0150955.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Capela</surname><given-names>JP</given-names></name>, <name><surname>Carmo</surname><given-names>H</given-names></name>, <name><surname>Remiao</surname><given-names>F</given-names></name>, <name><surname>Bastos</surname><given-names>ML</given-names></name>, <name><surname>Meisel</surname><given-names>A</given-names></name>, <name><surname>Carvalho</surname><given-names>F</given-names></name>. <article-title>Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview</article-title>. <source>Mol Neurobiol</source>. <year>2009</year>;<volume>39</volume>(<issue>3</issue>):<fpage>210</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12035-009-8064-1">10.1007/s12035-009-8064-1</ext-link></comment>
<pub-id pub-id-type="pmid">19373443</pub-id></mixed-citation></ref><ref id="pone.0150955.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Carvalho</surname><given-names>M</given-names></name>, <name><surname>Carmo</surname><given-names>H</given-names></name>, <name><surname>Costa</surname><given-names>VM</given-names></name>, <name><surname>Capela</surname><given-names>JP</given-names></name>, <name><surname>Pontes</surname><given-names>H</given-names></name>, <name><surname>Remiao</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Toxicity of amphetamines: an update</article-title>. <source>Arch Toxicol</source>. <year>2012</year>;<volume>86</volume>(<issue>8</issue>):<fpage>1167</fpage>&#x02013;<lpage>231</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00204-012-0815-5">10.1007/s00204-012-0815-5</ext-link></comment>
<pub-id pub-id-type="pmid">22392347</pub-id></mixed-citation></ref><ref id="pone.0150955.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Antolino-Lobo</surname><given-names>I</given-names></name>, <name><surname>Meulenbelt</surname><given-names>J</given-names></name>, <name><surname>Nijmeijer</surname><given-names>SM</given-names></name>, <name><surname>Scherpenisse</surname><given-names>P</given-names></name>, <name><surname>van den Berg</surname><given-names>M</given-names></name>, <name><surname>van Duursen</surname><given-names>MB</given-names></name>. <article-title>Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity</article-title>. <source>Drug Metab Dispos</source>. <year>2010</year>;<volume>38</volume>(<issue>7</issue>):<fpage>1105</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.110.032359">10.1124/dmd.110.032359</ext-link></comment>
<pub-id pub-id-type="pmid">20388857</pub-id></mixed-citation></ref><ref id="pone.0150955.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Monks</surname><given-names>TJ</given-names></name>, <name><surname>Jones</surname><given-names>DC</given-names></name>, <name><surname>Bai</surname><given-names>F</given-names></name>, <name><surname>Lau</surname><given-names>SS</given-names></name>. <article-title>The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity</article-title>. <source>Ther Drug Monit</source>. <year>2004</year>;<volume>26</volume>(<issue>2</issue>):<fpage>132</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="pmid">15228153</pub-id></mixed-citation></ref><ref id="pone.0150955.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Easton</surname><given-names>N</given-names></name>, <name><surname>Marsden</surname><given-names>CA</given-names></name>. <article-title>Ecstasy: are animal data consistent between species and can they translate to humans?</article-title>. <source>J Psychopharmacol</source>. <year>2006</year>;<volume>20</volume>(<issue>2</issue>):<fpage>194</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="pmid">16510478</pub-id></mixed-citation></ref><ref id="pone.0150955.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>McCann</surname><given-names>UD</given-names></name>, <name><surname>Szabo</surname><given-names>Z</given-names></name>, <name><surname>Vranesic</surname><given-names>M</given-names></name>, <name><surname>Palermo</surname><given-names>M</given-names></name>, <name><surname>Mathews</surname><given-names>WB</given-names></name>, <name><surname>Ravert</surname><given-names>HT</given-names></name>, <etal>et al</etal>
<article-title>Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2008</year>;<volume>200</volume>(<issue>3</issue>):<fpage>439</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">18661256</pub-id></mixed-citation></ref><ref id="pone.0150955.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Gollamudi</surname><given-names>R</given-names></name>, <name><surname>Ali</surname><given-names>SF</given-names></name>, <name><surname>Lipe</surname><given-names>G</given-names></name>, <name><surname>Newport</surname><given-names>G</given-names></name>, <name><surname>Webb</surname><given-names>P</given-names></name>, <name><surname>Lopez</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA</article-title>. <source>Neurotoxicology</source>. <year>1989</year>;<volume>10</volume>(<issue>3</issue>):<fpage>455</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="pmid">2576302</pub-id></mixed-citation></ref><ref id="pone.0150955.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Steuer</surname><given-names>AE</given-names></name>, <name><surname>Schmidhauser</surname><given-names>C</given-names></name>, <name><surname>Schmid</surname><given-names>Y</given-names></name>, <name><surname>Rickli</surname><given-names>A</given-names></name>, <name><surname>Liechti</surname><given-names>ME</given-names></name>, <name><surname>Kraemer</surname><given-names>T</given-names></name>. <article-title>Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites following controlled MDMA administration to humans</article-title>. <source>Drug Metab and Dispos</source>. <year>2015</year>;<volume>43</volume>(<issue>12</issue>):<fpage>1864</fpage>&#x02013;<lpage>71</lpage>.</mixed-citation></ref><ref id="pone.0150955.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Schwaninger</surname><given-names>AE</given-names></name>, <name><surname>Meyer</surname><given-names>MR</given-names></name>, <name><surname>Barnes</surname><given-names>AJ</given-names></name>, <name><surname>Kolbrich-Spargo</surname><given-names>EA</given-names></name>, <name><surname>Gorelick</surname><given-names>DA</given-names></name>, <name><surname>Goodwin</surname><given-names>RS</given-names></name>, <etal>et al</etal>
<article-title>Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration</article-title>. <source>Clin Chem</source>. <year>2011</year>;<volume>57</volume>(<issue>12</issue>):<fpage>1748</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1373/clinchem.2011.172254">10.1373/clinchem.2011.172254</ext-link></comment>
<pub-id pub-id-type="pmid">21980168</pub-id></mixed-citation></ref><ref id="pone.0150955.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Kreth</surname><given-names>K</given-names></name>, <name><surname>Kovar</surname><given-names>K</given-names></name>, <name><surname>Schwab</surname><given-names>M</given-names></name>, <name><surname>Zanger</surname><given-names>UM</given-names></name>. <article-title>Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs</article-title>. <source>Biochem Pharmacol</source>. <year>2000</year>;<volume>59</volume>(<issue>12</issue>):<fpage>1563</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="pmid">10799653</pub-id></mixed-citation></ref><ref id="pone.0150955.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Meyer</surname><given-names>MR</given-names></name>, <name><surname>Peters</surname><given-names>FT</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic MDMA and its enantiomers</article-title>. <source>Drug Metab Dispos</source>. <year>2008</year>;<volume>36</volume>(<issue>11</issue>):<fpage>2345</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.108.021543">10.1124/dmd.108.021543</ext-link></comment>
<pub-id pub-id-type="pmid">18725511</pub-id></mixed-citation></ref><ref id="pone.0150955.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Maurer</surname><given-names>HH</given-names></name>, <name><surname>Bickeboeller-Friedrich</surname><given-names>J</given-names></name>, <name><surname>Kraemer</surname><given-names>T</given-names></name>, <name><surname>Peters</surname><given-names>FT</given-names></name>. <article-title>Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy")</article-title>. <source>Toxicol Lett</source>. <year>2000</year>;<volume>112&#x02013;113</volume>:<fpage>133</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="pmid">10720722</pub-id></mixed-citation></ref><ref id="pone.0150955.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry</article-title>. <source>Ther Drug Monit</source>. <year>1996</year>;<volume>18</volume>(<issue>4</issue>):<fpage>465</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="pmid">8857570</pub-id></mixed-citation></ref><ref id="pone.0150955.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>de la Torre</surname><given-names>R</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <name><surname>Pizarro</surname><given-names>N</given-names></name>, <name><surname>Abanades</surname><given-names>S</given-names></name>, <name><surname>Segura</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition</article-title>. <source>Ther Drug Monit</source>. <year>2004</year>;<volume>26</volume>(<issue>2</issue>):<fpage>137</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="pmid">15228154</pub-id></mixed-citation></ref><ref id="pone.0150955.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Meyer</surname><given-names>MR</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation</article-title>. <source>Chemical Res Toxicol</source>. <year>2009</year>;<volume>22</volume>(<issue>6</issue>):<fpage>1205</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="pone.0150955.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Schwaninger</surname><given-names>AE</given-names></name>, <name><surname>Meyer</surname><given-names>MR</given-names></name>, <name><surname>Zapp</surname><given-names>J</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides</article-title>. <source>Drug Metab Dispos</source>. <year>2009</year>;<volume>37</volume>(<issue>11</issue>):<fpage>2212</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.109.029215">10.1124/dmd.109.029215</ext-link></comment>
<pub-id pub-id-type="pmid">19666989</pub-id></mixed-citation></ref><ref id="pone.0150955.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Schwaninger</surname><given-names>AE</given-names></name>, <name><surname>Meyer</surname><given-names>MR</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine metabolites 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach</article-title>. <source>Drug Metab Dispos</source>. <year>2011</year>;<volume>39</volume>(<issue>11</issue>):<fpage>1998</fpage>&#x02013;<lpage>2002</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.111.041129">10.1124/dmd.111.041129</ext-link></comment>
<pub-id pub-id-type="pmid">21795466</pub-id></mixed-citation></ref><ref id="pone.0150955.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Fallon</surname><given-names>JK</given-names></name>, <name><surname>Kicman</surname><given-names>AT</given-names></name>, <name><surname>Henry</surname><given-names>JA</given-names></name>, <name><surname>Milligan</surname><given-names>PJ</given-names></name>, <name><surname>Cowan</surname><given-names>DA</given-names></name>, <name><surname>Hutt</surname><given-names>AJ</given-names></name>. <article-title>Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans</article-title>. <source>Clin Chem</source>. <year>1999</year>;<volume>45</volume>(<issue>7</issue>):<fpage>1058</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="pmid">10388483</pub-id></mixed-citation></ref><ref id="pone.0150955.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Kraemer</surname><given-names>T</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives</article-title>. <source>Ther Drug Monit</source>. <year>2002</year>;<volume>24</volume>(<issue>2</issue>):<fpage>277</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="pmid">11897973</pub-id></mixed-citation></ref><ref id="pone.0150955.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>FT</given-names></name>, <name><surname>Samyn</surname><given-names>N</given-names></name>, <name><surname>Wahl</surname><given-names>M</given-names></name>, <name><surname>Kraemer</surname><given-names>T</given-names></name>, <name><surname>De Boeck</surname><given-names>G</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS</article-title>. <source>J Anal Toxicol</source>. <year>2003</year>;<volume>27</volume>(<issue>8</issue>):<fpage>552</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">14670133</pub-id></mixed-citation></ref><ref id="pone.0150955.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Pizarro</surname><given-names>N</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Pujadas</surname><given-names>M</given-names></name>, <name><surname>Peiro</surname><given-names>AM</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <name><surname>Joglar</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)</article-title>. <source>Drug Metab Dispos</source>. <year>2004</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1001</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">15319342</pub-id></mixed-citation></ref><ref id="pone.0150955.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Laine</surname><given-names>R</given-names></name>. <article-title>Metabolic stability: main enzymes involved and best tools to assess it</article-title>. <source>Curr Drug Metab</source>. <year>2008</year>;<volume>9</volume>(<issue>9</issue>):<fpage>921</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">18991589</pub-id></mixed-citation></ref><ref id="pone.0150955.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>SF</given-names></name>. <article-title>Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II</article-title>. <source>Clin Pharmacokinet</source>. <year>2009</year>;<volume>48</volume>(<issue>12</issue>):<fpage>761</fpage>&#x02013;<lpage>804</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2165/11318070-000000000-00000">10.2165/11318070-000000000-00000</ext-link></comment>
<pub-id pub-id-type="pmid">19902987</pub-id></mixed-citation></ref><ref id="pone.0150955.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Segura</surname><given-names>M</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Pichini</surname><given-names>S</given-names></name>, <name><surname>Peiro</surname><given-names>AM</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <name><surname>Ramirez</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe</article-title>. <source>Clin Pharmacokinet</source>. <year>2005</year>;<volume>44</volume>(<issue>6</issue>):<fpage>649</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="pmid">15910012</pub-id></mixed-citation></ref><ref id="pone.0150955.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Schmid</surname><given-names>Y</given-names></name>, <name><surname>Rickli</surname><given-names>A</given-names></name>, <name><surname>Schaffner</surname><given-names>A</given-names></name>, <name><surname>Duthaler</surname><given-names>U</given-names></name>, <name><surname>Grouzmann</surname><given-names>E</given-names></name>, <name><surname>Hysek</surname><given-names>CM</given-names></name>, <etal>et al</etal>
<article-title>Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2015</year>;<volume>353</volume>(<issue>1</issue>):<fpage>102</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/jpet.114.222356">10.1124/jpet.114.222356</ext-link></comment>
<pub-id pub-id-type="pmid">25655950</pub-id></mixed-citation></ref><ref id="pone.0150955.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>JW</given-names></name>, <name><surname>Pradko</surname><given-names>JF</given-names></name>, <name><surname>Muir</surname><given-names>KT</given-names></name>. <article-title>Bupropion for major depressive disorder: pharmacokinetic and formulation considerations</article-title>. <source>Clin Ther</source>. <year>2005</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1685</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="pmid">16368442</pub-id></mixed-citation></ref><ref id="pone.0150955.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Hughes</surname><given-names>JR</given-names></name>, <name><surname>Goldstein</surname><given-names>MG</given-names></name>, <name><surname>Hurt</surname><given-names>RD</given-names></name>, <name><surname>Shiffman</surname><given-names>S</given-names></name>. <article-title>Recent advances in the pharmacotherapy of smoking</article-title>. <source>J Am Med Assoc</source>. <year>1999</year>;<volume>281</volume>(<issue>1</issue>):<fpage>72</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0150955.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Coles</surname><given-names>R</given-names></name>, <name><surname>Kharasch</surname><given-names>ED</given-names></name>. <article-title>Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>. <year>2007</year>;<volume>857</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="pmid">17656162</pub-id></mixed-citation></ref><ref id="pone.0150955.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Kotlyar</surname><given-names>M</given-names></name>, <name><surname>Brauer</surname><given-names>LH</given-names></name>, <name><surname>Tracy</surname><given-names>TS</given-names></name>, <name><surname>Hatsukami</surname><given-names>DK</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Bronars</surname><given-names>CA</given-names></name>, <etal>et al</etal>
<article-title>Inhibition of CYP2D6 activity by bupropion</article-title>. <source>J Clin Psychopharmacol</source>. <year>2005</year>;<volume>25</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">15876900</pub-id></mixed-citation></ref><ref id="pone.0150955.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Reese</surname><given-names>MJ</given-names></name>, <name><surname>Wurm</surname><given-names>RM</given-names></name>, <name><surname>Muir</surname><given-names>KT</given-names></name>, <name><surname>Generaux</surname><given-names>GT</given-names></name>, <name><surname>St John-Williams</surname><given-names>L</given-names></name>, <name><surname>McConn</surname><given-names>DJ</given-names></name>. <article-title>An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction</article-title>. <source>Drug Metab Dispos</source>. <year>2008</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1198</fpage>&#x02013;<lpage>201</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/dmd.107.020198">10.1124/dmd.107.020198</ext-link></comment>
<pub-id pub-id-type="pmid">18420781</pub-id></mixed-citation></ref><ref id="pone.0150955.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Steuer</surname><given-names>AE</given-names></name>, <name><surname>Schmidhauser</surname><given-names>C</given-names></name>, <name><surname>Liechti</surname><given-names>ME</given-names></name>, <name><surname>Kraemer</surname><given-names>T</given-names></name>. <article-title>Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma</article-title>. <source>Drug Test Anal</source>. <year>2015</year>;<volume>7</volume>(<issue>7</issue>):<fpage>592</fpage>&#x02013;<lpage>602</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/dta.1740">10.1002/dta.1740</ext-link></comment>
<pub-id pub-id-type="pmid">25371386</pub-id></mixed-citation></ref><ref id="pone.0150955.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Hicks</surname><given-names>JK</given-names></name>, <name><surname>Swen</surname><given-names>JJ</given-names></name>, <name><surname>Thorn</surname><given-names>CF</given-names></name>, <name><surname>Sangkuhl</surname><given-names>K</given-names></name>, <name><surname>Kharasch</surname><given-names>ED</given-names></name>, <name><surname>Ellingrod</surname><given-names>VL</given-names></name>, <etal>et al</etal>
<article-title>Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants</article-title>. <source>Clin Pharmacol Ther</source>. <year>2013</year>;<volume>93</volume>(<issue>5</issue>):<fpage>402</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/clpt.2013.2">10.1038/clpt.2013.2</ext-link></comment>
<pub-id pub-id-type="pmid">23486447</pub-id></mixed-citation></ref><ref id="pone.0150955.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Trojan</surname><given-names>A</given-names></name>, <name><surname>Vergopoulos</surname><given-names>A</given-names></name>, <name><surname>Breitenstein</surname><given-names>U</given-names></name>, <name><surname>Seifert</surname><given-names>B</given-names></name>, <name><surname>Rageth</surname><given-names>C</given-names></name>, <name><surname>Joechle</surname><given-names>W</given-names></name>. <article-title>The discriminatory value of CYP2D6 genotyping in predicting the dextromethorphan/dextrorphan phenotype in women with breast cancer</article-title>. <source>Breast care</source>. <year>2012</year>;<volume>7</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="pmid">22553469</pub-id></mixed-citation></ref><ref id="pone.0150955.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>FT</given-names></name>, <name><surname>Hartung</surname><given-names>M</given-names></name>, <name><surname>Herbold</surname><given-names>M</given-names></name>, <name><surname>Schmitt</surname><given-names>G</given-names></name>, <name><surname>Daldrup</surname><given-names>T</given-names></name>, <name><surname>Musshoff</surname><given-names>F</given-names></name>. <article-title>Anhang B zur Richtlinie der GTFCh zur Qualit&#x000e4;tssicherung bei forensisch-toxikologischen Untersuchungen. Anforderungen an die Validierung von Analysenmethoden</article-title>. <source>Toxichem Krimtech</source>. <year>2009</year>;<volume>76</volume>:<fpage>185</fpage>.</mixed-citation></ref><ref id="pone.0150955.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>FT</given-names></name>, <name><surname>Maurer</surname><given-names>HH</given-names></name>. <article-title>Bioanalytical method validation and its implications for forensic and clinical toxicology: a review</article-title>. <source>Accred Qual Assur</source>. <year>2002</year>;<volume>7</volume>(<issue>11</issue>):<fpage>441</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0150955.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Hysek</surname><given-names>CM</given-names></name>, <name><surname>Simmler</surname><given-names>LD</given-names></name>, <name><surname>Nicola</surname><given-names>VG</given-names></name>, <name><surname>Vischer</surname><given-names>N</given-names></name>, <name><surname>Donzelli</surname><given-names>M</given-names></name>, <name><surname>Krahenbuhl</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study</article-title>. <source>PLos One</source>. <year>2012</year>;<volume>7</volume>(<issue>5</issue>):<fpage>e36476</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0036476">10.1371/journal.pone.0036476</ext-link></comment>
<pub-id pub-id-type="pmid">22574166</pub-id></mixed-citation></ref><ref id="pone.0150955.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Felim</surname><given-names>A</given-names></name>, <name><surname>Herrera</surname><given-names>G</given-names></name>, <name><surname>Neudorffer</surname><given-names>A</given-names></name>, <name><surname>Blanco</surname><given-names>M</given-names></name>, <name><surname>O'Connor</surname><given-names>JE</given-names></name>, <name><surname>Largeron</surname><given-names>M</given-names></name>. <article-title>Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): comparison with related catecholamines</article-title>. <source>Chem Res Toxicol</source>. <year>2010</year>;<volume>23</volume>(<issue>1</issue>):<fpage>211</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/tx9003374">10.1021/tx9003374</ext-link></comment>
<pub-id pub-id-type="pmid">20017534</pub-id></mixed-citation></ref><ref id="pone.0150955.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>CM</given-names></name>, <name><surname>Neudorffer</surname><given-names>A</given-names></name>, <name><surname>Largeron</surname><given-names>M</given-names></name>. <article-title>A convenient biomimetic synthesis of optically active putative neurotoxic metabolites of MDMA ("ecstasy") from R-(-)- and S-(+)-N-methyl-alpha-methyldopamine precursors</article-title>. <source>Org Biomol Chem</source>. <year>2012</year>;<volume>10</volume>(<issue>18</issue>):<fpage>3739</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1039/c2ob25245g">10.1039/c2ob25245g</ext-link></comment>
<pub-id pub-id-type="pmid">22456797</pub-id></mixed-citation></ref><ref id="pone.0150955.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Schindler</surname><given-names>CW</given-names></name>, <name><surname>Thorndike</surname><given-names>EB</given-names></name>, <name><surname>Blough</surname><given-names>BE</given-names></name>, <name><surname>Tella</surname><given-names>SR</given-names></name>, <name><surname>Goldberg</surname><given-names>SR</given-names></name>, <name><surname>Baumann</surname><given-names>MH</given-names></name>. <article-title>Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats</article-title>. <source>Br J Pharmacol</source>. <year>2014</year>;<volume>171</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bph.12423">10.1111/bph.12423</ext-link></comment>
<pub-id pub-id-type="pmid">24328722</pub-id></mixed-citation></ref><ref id="pone.0150955.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Segura</surname><given-names>M</given-names></name>, <name><surname>Ortuno</surname><given-names>J</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>McLure</surname><given-names>JA</given-names></name>, <name><surname>Pujadas</surname><given-names>M</given-names></name>, <name><surname>Pizarro</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans</article-title>. <source>Chem Res Toxicol</source>. <year>2001</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1203</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">11559034</pub-id></mixed-citation></ref><ref id="pone.0150955.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>AR</given-names></name>, <name><surname>Mechan</surname><given-names>AO</given-names></name>, <name><surname>Elliott</surname><given-names>JM</given-names></name>, <name><surname>O'Shea</surname><given-names>E</given-names></name>, <name><surname>Colado</surname><given-names>MI</given-names></name>. <article-title>The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")</article-title>. <source>Pharmacol Rev</source>. <year>2003</year>;<volume>55</volume>(<issue>3</issue>):<fpage>463</fpage>&#x02013;<lpage>508</lpage>. <pub-id pub-id-type="pmid">12869661</pub-id></mixed-citation></ref><ref id="pone.0150955.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>FT</given-names></name>, <name><surname>Samyn</surname><given-names>N</given-names></name>, <name><surname>Lamers</surname><given-names>C</given-names></name>, <name><surname>Riedel</surname><given-names>W</given-names></name>, <name><surname>Kraemer</surname><given-names>T</given-names></name>, <name><surname>de Boeck</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective determination of the designer drugs MDA, MDMA (ecstasy) and MDEA and its application to samples from a controlled study with MDMA</article-title>. <source>Clin Chem</source>. <year>2005</year>;<volume>51</volume>:<fpage>1811</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="pmid">16099938</pub-id></mixed-citation></ref><ref id="pone.0150955.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>de la Torre</surname><given-names>R</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Mathuna</surname><given-names>BO</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <name><surname>Pizarro</surname><given-names>N</given-names></name>, <name><surname>Segura</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2005</year>;<volume>61</volume>(<issue>7</issue>):<fpage>551</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="pmid">16041599</pub-id></mixed-citation></ref><ref id="pone.0150955.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Kharasch</surname><given-names>ED</given-names></name>, <name><surname>Mitchell</surname><given-names>D</given-names></name>, <name><surname>Coles</surname><given-names>R</given-names></name>. <article-title>Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>(<issue>4</issue>):<fpage>464</fpage>&#x02013;<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/0091270008314254">10.1177/0091270008314254</ext-link></comment>
<pub-id pub-id-type="pmid">18287571</pub-id></mixed-citation></ref><ref id="pone.0150955.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>She</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>Z</given-names></name>, <name><surname>Dai</surname><given-names>R</given-names></name>. <article-title>The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors</article-title>. <source>J Enzyme Inhibit Med Chem</source>. <year>2011</year>;<volume>26</volume>(<issue>3</issue>):<fpage>386</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="pone.0150955.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Tomillero</surname><given-names>A</given-names></name>, <name><surname>Perez-Mana</surname><given-names>C</given-names></name>, <name><surname>Yubero</surname><given-names>S</given-names></name>, <name><surname>Papaseit</surname><given-names>E</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <etal>et al</etal>
<article-title>Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart</article-title>. <source>Eur Neuropsychopharmacol</source>. <year>2015</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1637</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.euroneuro.2015.05.007">10.1016/j.euroneuro.2015.05.007</ext-link></comment>
<pub-id pub-id-type="pmid">26073279</pub-id></mixed-citation></ref><ref id="pone.0150955.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>de la Torre</surname><given-names>R</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Ortuno</surname><given-names>J</given-names></name>, <name><surname>Mas</surname><given-names>M</given-names></name>, <name><surname>Brenneisen</surname><given-names>R</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <etal>et al</etal>
<article-title>Non-linear pharmacokinetics of MDMA ('ecstasy') in humans</article-title>. <source>Br J Clin Pharmacol</source>. <year>2000</year>;<volume>49</volume>(<issue>2</issue>):<fpage>104</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">10671903</pub-id></mixed-citation></ref><ref id="pone.0150955.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>de la Torre</surname><given-names>R</given-names></name>, <name><surname>Farre</surname><given-names>M</given-names></name>, <name><surname>Roset</surname><given-names>PN</given-names></name>, <name><surname>Hernandez</surname><given-names>LC</given-names></name>, <name><surname>Mas</surname><given-names>M</given-names></name>, <name><surname>Ortuno</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Pharmacology of MDMA in humans</article-title>. <source>Ann N Y Acad Sci</source>. <year>2000</year>;<volume>914</volume>:<fpage>225</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="pmid">11085324</pub-id></mixed-citation></ref></ref-list></back></article>